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Abstract 
Membrane proteins are influenced by the dynamic lipid membrane environment, which can 
impart stability, mediate protein interactions, and provide highly selective contacts essential 
for function. Membrane proteins can also bind endogenous lipid ligands or are able to be 
allosterically modulated by lipids, many of which are thought to access their specific binding 
sites via the cell membrane. 
N-arachidonyl glycine (NAGly) is a bioactive lipid that is found in its highest concentrations 
within the spinal cord and may play an important role in endogenous regulation of glycinergic 
neurotransmission and pain perception through inhibition of the glycine transporter, GlyT2. In 
addition to NAGly, a number of lipid inhibitors of GlyT2 have been identified. These 
compounds are comprised of a long flexible unsaturated acyl tail conjugated to an amino acid 
or amino acid derivative head group. The aims of my study were two-fold; first to identify new, 
more potent, lipid inhibitors and develop a structure activity relationship for these compounds; 
and second, to elucidate the molecular mechanisms of inhibition. Wild type and mutant GlyT2 
transporters were expressed in Xenopus laevis oocytes with glycine transport and the 
subsequent inhibition of transport measured using two-electrode voltage clamp 
electrophysiology, and radiolabelled uptake of glycine. 
A library of 55 N-acyl amino acids with varying head and tail groups were synthesised and 
tested at both GlyT2 and the closely related glycine transporter, GlyT1. Two distinct groups of 
compounds were tested: the first group maintaining a glycine head group and altering the lipid 
tail; and the second conjugating the [C18 ω9] oleoyl tail to amino acids with varying properties. 
I found the lipid constituent of the acyl-glycine analogues is essential for specific interactions 
and the mechanism of inhibition and is not merely a non-selective, sticky adjunct. There was 
an ideal chain length, with an order of potency C18 > C16 > C14, and stringently defined 
double bond conformation and position. Conservative differences between compounds are 
sufficient to impart or remove inhibitory activity which validates highly specific binding to a 
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subtype specific, allosteric pocket. While changing the tail did not greatly alter potency, 
analogues where the head group was altered significantly influenced apparent affinity. Acyl 
amino acids containing an aromatic or positively charged side chain conferred the highest 
apparent affinity, with C16 ω3 L-Lys possessing the highest potency (10.7 nM). 12 compounds 
inhibited GlyT2 < 100nM, and one of these inhibitors, oleoyl D-Lys, is also metabolically stable 
and produces analgesia in a rat model of neuropathic pain. 
Mutagenesis of extracellular loop 4 (EL4), and transmembrane helices TM5 and TM8 suggest 
that the allosteric binding site is comprised of a cluster of aromatic residues which may strongly 
coordinate aromatic or positively charged head groups of the most potent analogues. 
Additionally, changing the properties of a membrane facing residue alters the otherwise slow 
washout of lipids. From these results, in addition to dynamic docking studies, it is proposed 
that acyl amino acids may first diffuse into the lipid bilayer and interact with regions of GlyT2 
at the protein-membrane interface. Acyl amino acids then access their final binding site formed 
by aliphatic and aromatic residues from TM5, TM8, and EL4. It has previously been shown 
that EL4 undergoes important conformational changes in this family of transporters, where 
EL4 shifts into the outward facing vestibule to occlude the extracellular side and continue the 
transport cycle. Acyl amino acids may therefore inhibit GlyT2 by stabilising EL4 in a 
conformation that does not favour transport. The combination of structure-activity studies with 
molecular insights provides key information on the mechanism of inhibition which will drive 
further generation of GlyT2 inhibitors for the treatment of neuropathic pain. 
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Chapter 1: Literature review 
1.1  Chronic pain 
Approximately 29% of the Australian population are suffering from chronic pain conditions 
(Stollznow Research, 2010), with a high proportion of those affected being of working age, 
causing a deficit of $34 billion annually to the Australian economy through health care costs 
and loss of productivity (most recent figures by Access Economics, 2007). Chronic pain cases 
make up the majority of visits to general practitioners and are additionally associated with a 
number of psychiatric comorbidities (Gatchel et al., 2007). In a study of 1,595 chronic pain 
patients, 64% also suffered from a psychiatric condition compared with 15% in the general 
population (Dersh et al., 2002). These concomitant conditions are often a greater predictor of 
disability than the severity of chronic pain (Ormel et al., 1994),and are likely a direct 
consequence of the debilitating nature of the disease, as only 16% of patients are satisfied 
with their pain management (Stollznow Research, 2010) 
There is a great need to develop new drugs to treat chronic pain as current analgesics are 
ineffective, or have an unacceptable side effect profile and potential for abuse. For example, 
opioids have traditionally been used for the treatment of chronic pain due to their analgesic 
effects via action on mu (μ) opioid receptors. However, concerns about long-term safety and 
efficacy have limited their use (Rosenblum et al., 2008). Other therapeutics indicated for 
treatment of other diseases, such as tricyclic antidepressants and anticonvulsants, are often 
prescribed to treat chronic pain (Fornasari, 2017), but majority of cases are refractory to these 
conventional drugs. It is clear that current treatments are ineffective at treating the complex 
spectrum of symptoms that underlies neuropathic pain, and new targets which are involved in 
the formation and progression of the disease must be explored. 
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1.1.1 Neuropathic pain 
Neuropathic pain is a prevalent form of chronic pain, characterised by associated hyperalgesia 
and allodynia, which produce distinctive symptoms of numbness, burning, shooting, and 
electric-like pain in sufferers (Costigan et al., 2009). Hyperalgesia is defined as a lowered 
reduction in the pain threshold, which amplifies pain sensation, and often occurs alongside 
allodynia, an inappropriate pain response to innocuous stimuli (Scholz & Woolf, 2002). 
Disease or injury to peripheral nerves can cause long-term neuropathic pain which persists 
well after the site of injury has healed. Damage and inflammation at the peripheral site alone, 
however, cannot explain the ongoing symptoms. Changes within the central nervous system 
produce disordered synaptic pathways and central sensitisation, which contribute to the 
pathology of neuropathic pain (Latremoliere & Woolf, 2009). 
1.1.2 Nociception 
In normal nociception, sensory receptors have a typical threshold of activation. Certain stimuli 
such as intense heat and pressure, but not light touch and low temperature, will stimulate 
nociceptors (Julius & Basbaum, 2001). Following activation, primary sensory neurons 
innervate the spinal cord dorsal horn as the first point of dispatch before transmission to the 
brain for cognitive processing (Todd, 2010). 
Primary afferent neurons terminate in distinctive locations within the spinal cord, with 
nociceptive fine myelinated Aδ-, and unmyelinated C-fibers innervating the superficial region 
(laminae I-II), and lower- threshold, non-noxious mechanoreceptive Aβ-fibers terminating in 
deeper laminae IIi-VI (Todd, 2010) (Figure 1.1, Vandenberg et al., 2014). Nociceptive 
projection neurons in lamina I express neurokinin 1 receptors (NK1) which are activated 
following direct stimulation by C-fibres, or by excitatory interneurons in lamina II (Takazawa & 
MacDermott, 2010). Inhibitory glycinergic interneurons in lamina III synapse onto excitatory 
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neurons, including protein kinase Cγ (PKCγ) positive neurons, where they inhibit low-
threshold, non-noxious information from entering the pain pathway. 
 
Figure 1.1. Nociceptive and non-noxious pathways in the dorsal horn of the spinal cord. 
Left panel: in normal physiological states, excitatory Aβ (light touch) sensory inputs converge 
onto excitatory interneurons [green cells; E, some of which are protein kinase Cγ (PKCγ)-
positive] in lamina II of the superficial dorsal horn, as well as glycinergic neurons in lamina III 
[blue cells; Gly]. Concurrent activation of these glycinergic interneurons produces strong feed-
forward inhibition of lamina II excitatory interneurons (green; E) that prevents non-noxious 
sensory information from invading pain transmission neurons in lamina I [red cell; neurokinin 
1 (nk1) receptor positive] (Vandenberg et al., 2014). Right panel: a loss of glycinergic inputs 
allow for innocuous stimuli to enter the pain pathway and increase transmission to the brain. 
 
1.1.3 The role of glycine in neuropathic pain 
A dysfunction of synaptic transmission can give rise to neuropathic pain, whereby a 
dominance of excitatory tone in the superficial neurons of the dorsal horn causes an excess 
of nerve firing in the ascending pain pathway (Latremoliere & Woolf, 2009; Takazawa & 
MacDermott, 2010). Nerve injury can, among other mechanisms, reduce the control 
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maintained by inhibitory neurons and allow for disinhibition of pain signalling to occur. Loss of 
inhibition can be due to a reduced synthesis and release of neurotransmitters or, more 
significantly, a loss of inhibitory neurons through N-methyl D-aspartate receptors (NMDAR) 
induced toxicity and apoptosis (Scholz et al., 2005). 
A recent study has shown that in a partial nerve ligation rat model of neuropathic pain, there 
is a reduction in electrically evoked glycinergic inhibitory post-synaptic currents (eIPSCs) of 
radial interneurons in the spinal cord (Figure 1.2, Imlach et al., 2016). These excitatory radial 
neurons in the spinal cord received reduced glycinergic inhibitory inputs. This may generate 
hyperexcitability and disinhibition of pain signalling. Disinhibition has been shown to increase 
the low-threshold activation of lamina II neurons, and the subsequent increase in excitatory 
post synaptic currents (EPSCs) activated by Aβ and Aδ fibres, which would allow for 
mechanical allodynia (Takazawa & MacDermott, 2010). 
 
Figure 1.2. Glycinergic neurotransmission is reduced in radial neurons of superficial 
dorsal horn after partial nerve ligation. Normalised glycinergic eIPSC values as a 
percentage of the total eIPSC for the neuron types following partial nerve ligation (red) and 
sham (grey) surgeries (*** p<0.001 , two way ANOVA, Sidak post-hoc multiple comparisons 
test) (adapted from Imlach et al., 2016). 
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Peripheral nerve injury can also lead to degeneration of peripheral C-fiber terminals and 
subsequent sprouting of Aβ fibers into higher regions of the spinal cord (laminae I-II), where 
they innervate nociceptive neurons (Scholz & Woolf, 2002). This muddling of sensory 
pathways can lead to stimulation of nociceptive transmission by innocuous stimuli. 
The network of altered synaptic transmission in the dorsal horn allows for excessive nerve 
firing in the ascending pain pathway. Glycine is the predominant inhibitory neurotransmitter in 
the spinal cord responsible for suppressing excitatory tone, and so it follows that a novel 
therapy involved in increasing glycine at inhibitory synapses may dampen spontaneous nerve 
activity and result in a reduction of associated pain symptoms. 
1.2 Glycinergic neurotransmission 
Inhibitory glycine receptors (GlyR) are pentameric ligand gated ion channels composed of 
subunits (α1-α4, β) which direct their differential expression and defines the physiological role 
of the receptor (Lynch, 2004; Malosio et al., 1991). When expressed postsynaptically in the 
brain stem and spinal cord, GlyRs are activated by glycine to generate hyperpolarisation to 
reduce neuronal firing and have been implicated in pain processing (Ahmadi et al., 2001). 
Presynaptic homomeric α3 glycine receptors have also been proposed to have a role in pain 
pathways, where activation of these receptors prompts presynaptic glycine release (Jeong et 
al., 2003). In addition to its actions at inhibitory synapses, glycine can diffuse to excitatory 
synapses where it can act as a co-agonist with glutamate at NMDARs (Supplisson & Bergman, 
1997). 
Following glycine release into inhibitory synapses, glycine levels increase from a resting 
concentration of 0.1-0.2 µM to millimolar concentrations (Eulenburg et al., 2005). Rapid 
removal of glycine is then required to terminate transmission and reduce diffusion to adjacent 
synapses. In order to sustain this tightly regulated concentration requirement, Na+/Cl- coupled 
transporters are employed to actively remove glycine from the synapse, resulting in a 
subsequent restoration of resting glycine levels (Zafra et al., 1995). 
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1.3 Glycine transporters 
There are two subtypes of glycine transporters which have been identified within the 
mammalian central nervous system, glycine transporter 1 (GlyT1) and glycine transporter 2 
(GlyT2) which share 48% amino acid sequence identity (Morrow et al., 1998). GlyT1 is 
preferentially expressed on astrocytes adjacent to both excitatory and inhibitory neurons 
allowing for regulation of glycine concentrations at both glutamatergic and glycinergic 
synapses. GlyT2 is almost exclusively expressed on presynaptic inhibitory glycinergic neurons 
(Zafra et al., 1995) (Figure 1.3, Vandenberg et al., 2014). 
 
Figure 1.3. The cycle of glycine action at inhibitory and excitatory synapses. Glycine is 
released into inhibitory synapses where it activates postsynaptic GlyRs (red). Glycine is 
cleared from the inhibitory synapse via GlyT2 (yellow) transporters on the presynaptic neuron 
and via GlyT1 (blue) transporters on adjacent astrocytes. At excitatory synapses glycine acts 
as a co-agonist with glutamate on NMDARs (green). The glycine is then cleared by GlyT1 on 
astrocytes and glutamatergic neurons (Vandenberg et al., 2014). 
 
The transport of glycine is thermodynamically unfavourable. To account for this GlyT1 and 
GlyT2 couple substrate transport to one Cl- ion and two Na+ ions or three Na+ ions respectively, 
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exploiting the ion gradients generated by Na+/K+-ATPase (Roux & Supplisson, 2000). As a 
result of the additional Na+ ion carried by GlyT2, the concentrating capacity for the transport 
of glycine by this subtype is greater. This facilitates the rapid reuptake of glycine into 
presynaptic terminals where the low affinity vesicular inhibitory amino acid transporter (VIAAT) 
can load glycine into vesicles to be recycled for further release (Roux & Supplisson, 2000). 
The substrate binding site of GlyT1 is somewhat larger than GlyT2 and is able to 
accommodate sarcosine, an N-methyl derivative of glycine, as well as the transport of glycine 
itself (Vandenberg et al., 2007). Conversely, there are no known substrates other than glycine 
for GlyT2 (Carland et al., 2018). 
The importance of GlyT1 and GlyT2 is demonstrated through knockout, or small interfering 
RNA (siRNA) knockdown of protein expression. Homozygous (GlyT1-/-) knockout mice 
experience severe motorsensory and respiratory deficits, which are fatal 6-14 hours following 
birth (Gomeza et al., 2003a). These mice also exhibit constant activation of glycine receptors, 
which suggests that in the absence of GlyT1, glycine is unable to be sufficiently cleared from 
the synapse. Conversely, electrophysiological recordings from GlyT2-/- mice show a reduction 
in postsynaptic glycinergic currents (Figure 1.4, Gomeza et al., 2003b), supporting the crucial 
role of GlyT2 in the recycling and release of glycine. The GlyT2 knockout phenotype is fatal 2 
weeks postnatal, where mice develop severe neuromotor disease, with symptoms reflective 
of hyperekplexia; strong tremor could be easily induced through touch, and mice experienced 
extreme muscle rigidity and were unable to right themselves (Gomeza et al., 2003b). Mutation 
of the human GlyT2 gene (SLC6A5) is the most common cause of presynaptic hyperekplexia, 
where mutations have been shown to affect GlyT2 localisation and expression, and/or a 
reduction in glycine reuptake through disruption of the glycine and ion binding sites (Carta et 
al., 2012; Eulenburg et al., 2006; Rees et al., 2006).  
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Figure 1.4. Glycine receptor mediated post synaptic currents in A. wild type GlyT2 (+/+) 
and B. knockout GlyT2 (-/-) mice (Gomeza et al., 2003b) 
 
Partial knockdown of glycine transporters using targeted siRNA reduces protein expression to 
~30% 3 days after injection (Morita et al., 2008). No apparent behavioural symptoms were 
observed. Furthermore, siRNA has an antiallodynic effect in rat models of neuropathic pain 
(Morita et al., 2008), further validating an analgesic role for glycine. While total removal of 
GlyT2 eliminates this route of glycine recycling, partial knockdown instead slows clearance 
from the synapse while still preserving glycine reuptake for vesicular refilling and further 
release. 
1.4 Glycine transport inhibitors 
Intrathecal injection of glycine reduces spontaneous nociception and neuronal dystrophy in 
rats (W. Huang & Simpson, 2000). Conversely, hyperalgesia and allodynia can be induced 
using the glycine receptor antagonist, strychnine (Yaksh, 1989). The role of glycine in the 
development of pain and its utility in producing analgesia has driven the development of a 
number of glycine transport inhibitors (Figure 1.5) for the treatment of neuropathic pain. 
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Figure 1.5. Structures of GlyT2 inhibitors. 
 
ALX1393 (Xu et al., 2005) and ORG25543 (Caulfield et al., 2001) were among the first potent 
inhibitors of GlyT2 to be developed. ALX1393 inhibits GlyT2 with an IC50 of 100 nM 
(Mingorance-Le Meur et al., 2013) and has been shown to be anti-allodynic when intrathecally 
or intravenously injected into rodents suffering from neuropathic pain (Haranishi et al., 2010; 
Morita et al., 2008; Xu et al., 2005). These anti-allodynic effects could be reversed using 
strychnine (Haranishi et al., 2010), confirming a glycinergic mechanism of analgesia where 
inhibition of GlyT2 by ALX1393 results in an increase of GlyR activation, probably through 
transient increases in the concentration of glycine within the synapse. 
Chronic application of ALX1393 does not affect the frequency of glycinergic miniature 
inhibitory postsynaptic currents (mIPSCs), but rather alters the ratio of gamma-aminobutyric 
acid (GABA) and glycine signalling (Xu et al., 2005). This is likely through the inhibition of 
glycine recycling by GlyT2 which would influence the VIAAT mediated loading of presynaptic 
vesicles and ultimately favour the release of GABA. This potential to alter the balance of 
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inhibitory neurotransmission may limit the use of ALX1393.  Application of ALX-1393 has since 
been implicated in producing significant adverse symptoms, including paresis or plegia, and 
severe respiratory depression (Hermanns et al., 2008), with similar respiratory effects, such 
as irregular respiratory rhythm, observed in mice deficient in presynaptic α3 receptors 
(Manzke et al., 2010), which suggests the symptoms occur through obstruction of presynaptic 
recycling mechanisms. Additionally, in a study measuring the in vivo target exposure of 
ALX1393 following intravenous injection (Mingorance-Le Meur et al., 2013), the free 
brain/plasma ratio was >0.05, 60 minutes post administration. At the maximal dose, the free 
concentration was 3-fold below the IC50 which suggests that ALX1393 may be unable to cross 
the blood brain barrier (BBB) in sufficient quantities to bind to the glycine transporter. ALX1393 
has also been shown to inhibit glycine uptake of GlyT1 expressing cells (IC50 4 µM) 
(Mingorance-Le Meur et al., 2013).  Despite ALX1393’s analgesic properties, adverse side 
effects, poor BBB permeability, and non-selectivity may limit its therapeutic use. 
ORG25543 is a potent inhibitor of GlyT2 (IC50 16 nM, Caulfield et al., 2001), and unlike 
ALX1393, has no appreciable activity at GlyT1. ORG25543 ameliorates hyperalgesia and 
allodynia in a number of pain models (Morita et al., 2008; Mingorance-Le Meur et al., 2013). 
Application of ORG25543 to mouse spinal cord slices shows changes in glycinergic 
neurotransmission and a decrease in the decay constant of mIPSCs (Bradaia et al., 2004), 
however exposure >10 minutes resulted in a long term reduction in IPSCs, likely through 
decreased glycine release into the synapse. Furthermore, glycinergic currents are not able to 
be restored following a washout period after ceasing ORG25543 application (Mingorance-Le 
Meur et al., 2013). This sustained, complete block of GlyT2 may prevent the recycling of 
glycine and lead to toxicity, mimicking the symptoms of a GlyT2 knockout phenotype. Acute 
dosing of ORG25543 produces excitotoxicity, hyperekplexia like symptoms such as tremor, 
and in severe cases death, as a result of its irreversibility (Mingorance-Le Meur et al., 2013). 
To prevent this, a series of analogues based on the structure of ORG25543 were synthesised 
and tested for their BBB permeability and toxicity profiles (Mingorance-Le Meur et al., 2013). 
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Compound 1 is one such compound with an IC50 of 100 nM, high BBB permeability, and 
reversibility and restoration of glycine currents following inhibition. Application of Compound 1 
to mice displayed no adverse side effects and so it is predicted that a GlyT2 inhibitor should 
be reversible to improve its therapeutic potential. 
More recently, Takahashi et al., (2014) synthesised a series of phenoxymethylbenzamides 
which are potent inhibitors of GlyT2. One analogue, GT-0198, displayed high selectivity at 
GlyT2 (IC50 105 nM) and a high brain/plasma ratio of 0.167 1 hr following oral administration 
(Takahashi et al., 2014). Intravenous, oral or intrathecal administration of GT-0198 has also 
been shown to be analgesic in a partial nerve ligation model of pain (Omori et al., 2015). 
Opiranserin (previously VVZ-149) is a drug under development by Vivozon indicated for post-
operative pain relief, and is currently in phase II clinical trials. Unlike classical GlyT2 inhibitors, 
opiranserin was developed with the aim of binding to multiple targets with similar affinity that 
may generate synergistic effects (Nedeljkovic et al., 2017; Pang et al., 2012). Opiranserin 
inhibits GlyT2 (IC50 860 nM), and is an antagonist at purine P2X3 receptors (IC50870 nM) and 
serotonin 5-HT2A receptors (IC50 1.3 µM). This multi-target approach may help to identify more 
efficacious analgesics for the treatment of neuropathic pain. 
1.5 Lipids as glycine transport inhibitors 
Another compound with multiple antinociceptive targets is N-arachidonyl glycine or NAGly 
(Figure 1.5, 1.6A), which in addition to inhibiting GlyT2 (Wiles et al., 2006), also targets T-type 
Ca2+ channels (Ross et al., 2009), COX-2 (Prusakiewicz et al., 2002), inhibitory glycine 
receptors (Yang et al., 2008), and may also activate orphan receptors including GPR55 
(Console-Bram et al., 2017) and GPR18 (Kohno et al., 2006). NAGly is a carboxylic acid 
derivative of anandamide and is endogenously produced through two distinct enzymatic 
pathways in the central nervous system (Bradshaw et al., 2009). NAGly is found in highest 
concentrations within the spinal cord and may play an important role in modulating pain 
(Huang et al., 2001). NAGly reduces mechanical allodynia and thermal hyperalgesia, which 
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are characteristic of chronic pain in both neuropathic and inflammatory rat models of pain, and 
does not generate any overt side effects (Succar et al., 2007; Vuong et al., 2008). Additionally, 
NAGly prolongs the time course of glycine at glycinergic synapses in lamina II of the superficial 
dorsal horn, an area responsible for integrating ascending pain information, and also prolongs 
the decay phase of evoked inhibitory postsynaptic currents, which suggests that NAGly may 
exert analgesia by increasing inhibitory tone at glycinergic neurons (Jeong et al., 2010). 
NAGly is a reversible, non-competitive inhibitor of GlyT2 (IC50 9 µM) and has no appreciable 
activity at GlyT1 (Wiles et al., 2006), or at the CB1 or CB2 cannabinoid receptors (Sheskin et 
al., 1997). Other N-arachidonyl amino acid conjugates (Figure 1.6A) also inhibit the GlyT2 
transporter, with an order of potency of NAGly > N-arachidonyl alanine > N-arachidonyl GABA 
(Wiles et al., 2006). These inhibitors are amphipathic and have the propensity to 
spontaneously form micelles at a characteristic critical micelle concentration (CMC). The CMC 
for NAGly is >30 µM which would limit the free diffusion and binding to GlyT2 above this 
concentration. For NAGly, the solubility of the compound is likely to limit the maximal level of 
inhibition and produce partial inhibition in in vivo and in vitro assays. N-oleoyl glycine (NOGly) 
similarly contains a glycine head group and has instead an ω9 monounsaturated 18-carbon 
tail. NOGly inhibits GlyT2 (Carland et al., 2013) with a lower level of maximal inhibition than 
NAGly, which plateaus at concentrations below its CMC, suggesting that the partial inhibition 
is a reflection of how the lipid binds to the transporter. 
Similarly, an endogenous acylcarnitine, oleoyl L-carnitine (OLCarn) inhibits GlyT2 (IC50 340 
nM, Carland et al., 2013). Two additional compounds containing the L-carnitine head group 
with tails of differing length and degree of saturation (Figure 1.6B), palmitoyl-L-carnitine and 
lauroyl-L-carnitine inhibit GlyT2 with IC50 values of 600 nM and > 10 µM respectively (Carland 
et al., 2013). Unlike the glycine conjugated inhibitors which were fully reversible 5 minutes 
after inhibition, OLCarn is very slowly reversible, with glycine currents not restored in the time 
frame of the assay (Carland et al., 2013). The reversibility of OLCarn can be accelerated by 
- 19 - 
 
adding bovine serum albumin or the lipid extruding compound β-cyclodextrin, which suggests 
that OLCarn may inhibit GlyT2 by binding within a membrane exposed site. 
 
Figure 1.6. Structures of known A. glycine conjugated and B. carnitine conjugated 
GlyT2 lipid inhibitors. 
 
Bioactive lipid inhibitors of GlyT2 are amphiphilic; comprised of a long flexible lipid tail and a 
polar head group. It has been demonstrated that both the head and tail group are important in 
conferring activity of these compounds (Carland et al., 2013, Wiles et al., 2006), though little 
is known about the molecular interactions with their target. A comprehensive structure activity 
relationship of these compounds is also yet to be understood. 
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1.6 Molecular basis for lipid inhibition of GlyT2 
Unlike other known inhibitors of GlyT2, which likely bind their bulky aromatic groups within the 
central cavity of GlyT2, lipid inhibitors are non-competitive (Wiles et al., 2006) and thought to 
act at an allosteric site. Previous studies using site-directed mutagenesis and chimeric 
GlyT1/GlyT2 transporters have revealed that extracellular loop 4 (EL4) plays an important role 
in the mechanism of inhibition by both glycine- and carnitine- conjugated lipid inhibitors 
(Edington et al., 2009; Carland et al., 2013), though the binding site has not been elucidated. 
No structures of the glycine transporter are available, and so crystal structures of homologues 
are utilised to understand the important conformational changes required for transport of 
glycine by GlyT2. 
GlyT2 belongs to the neurotransmitter sodium symporters (NSS) or SLC6 family of 
transporters, which are secondary active transporters that exploit the Na+ gradient to drive 
transport of amino acid and amino acid derivatives across cell membranes (Kristensen et al., 
2011). In addition to glycine transporters, members of this family include transporters for 
serotonin, dopamine, noradrenalin, and GABA. To date, crystal structures of the bacterial 
leucine transporter, LeuTAa (Krishnamurthy & Gouaux, 2012; Yamashita et al., 2005); the 
Drosophila melanogaster dopamine transporter, dDAT (Penmatsa et al., 2013, 2015; Wang et 
al., 2015); and the human serotonin transporter, hSERT (Coleman et al., 2016), have been 
resolved in a number of conformations and either, apo, substrate or inhibitor bound. 
1.6.1 Structures of the bacterial homologue LeuT 
LeuTAa (herein referred to as LeuT) is a bacterial leucine transporter from Aquifex aeolicus 
with homology to the NSS transporter family and shares ~20% amino acid identity with the 
glycine transporters. LeuT is well characterised and has been crystallised in a number of 
conformations; outward-facing, outward-facing with substrate bound (Yamashita et al., 2005), 
and inward-facing (Krishnamurthy & Gouaux, 2012) conformations which have been used to 
model the movement of LeuT through different stages of the transport cycle (Figure 1.7, 
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Krishnamurthy & Gouaux, 2012) (Chen & Chung, 2015; Forrest et al., 2008; Kazmier et al., 
2014; Penmatsa & Gouaux, 2014). 
LeuT contains twelve α-helical transmembrane (TM) domains oriented by a 
pseudosymmetrical axis whereby the first five transmembrane helices (TM1-5) mirror the 
second five helices (TM6-10) (Forrest et al., 2008). Two pairs of helices, TM1 and 6, and TM3 
and 8, form the core of the transporter and hold the leucine binding site and coordinate two 
Na+ ions for co-transport (Krishnamurthy et al., 2009). These sites are conserved in GlyT1 and 
GlyT2 (Vandenberg et al., 2007), with GlyT2 containing a third Na+ binding site located on the 
intracellular half of the transporter (Subramanian et al., 2016). 
The leucine binding site is dehydrated during transport, employing a conserved salt bridge 
between R30 (TM1) and D404 (TM10) (Figure 1.7) to reinforce the extracellular hydrophobic 
vestibule, and a thick intracellular gate comprising a complex hydrogen bond network and salt 
bridge to occlude water (Yamashita et al., 2005). The disruption and creation of these bonds 
generates significant structural changes which enable LeuT to oscillate between the outward 
facing and inward facing conformations (Forrest et al., 2008; Tavoulari et al., 2016), consistent 
with the alternating access mechanism of transport. 
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Figure 1.7. Schematic of transport in LeuT. Shown are structural elements and gating 
residues instrumental to conformational changes associated with the transition from the 
outward-open (a) to the outward-occluded state (b), and the inward-open state (c) 
(Krishnamurthy & Gouaux, 2012). 
 
In the outward-facing conformation, LeuT allows leucine and two Na+ ions to bind resulting in 
the movement of the extracellular loop EL4 into the extracellular facing hydrophobic vestibule 
(Figure 1.7a). EL4 packs adjacent to TM1b, TM3, TM7 and TM8, closing the extracellular gate 
and preventing release of the substrate into the extracellular space (Figure 7b). Unwound 
regions of TM1 and TM6 form hinge domains, permitting their intracellular halves to swing 
outward and expel leucine into the cytoplasm (Figure 7c, Krishnamurthy & Gouaux, 2012). 
1.6.2 Structures of the dopamine and serotonin transporters 
More recently, outward-open crystal structures of the related dDAT (Penmatsa et al., 2013, 
2015; Wang et al., 2015) and hSERT (Coleman et al., 2016) have been determined from 
Drosophila melanogaster and humans respectively. dDAT and hSERT are comprised of 
twelve TM helices which are pseudosymmetrically oriented, resembling the structure of LeuT. 
Substrates or inhibitors were observed bound in the primary substrate-binding cavity, with two 
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Na+ ions resolved in the same Na1 and Na2 sites as LeuT, and the co-transported Cl- ion 
coordinated by residues in TM2, TM6, and TM7 of dDAT (Penmatsa et al., 2013). 
Superimposition of dDAT and hSERT show a low (0.5 Å) root mean square deviation (RMSD) 
between core helices which coordinate substrate and ions; and conformational variation 
between TMs 9-12 as well as the flexible termini and extracellular loops EL2 and EL4 (Figure 
1.8, Coleman et al., 2016). The binding of substrates and inhibitors at dDAT and hSERT 
closely resemble that of LeuT, which suggests a common mechanism of transport for 
transporters with a LeuT-like fold. 
 
Figure 1.8. Alignment of SERT (pink) versus dDAT (grey) a, Overall alignment with TM1-
TM12; regions in SERT with structural differences are boxed. (S)-citalopram bound to the 
central (green) and allosteric (cyan) sites shown as sticks. b, Close up view of EL2, N-
acetylglucosamine (NAG; SERT) and the disulfide bridge between Cys200 and Cys209 are 
shown as sticks. c, View of EL4 (adapted from Coleman et al., 2016). 
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1.6.3 GlyT2 homology model 
GlyT2 is also predicted to possess the LeuT-like fold common among NSS transporters, and 
shares 50% sequence identity with dDAT. A homology model of GlyT2 was produced (Figure 
1.9, Subramanian et al., 2016) using protein fold recognition, where the amino acid sequence 
of GlyT2 was threaded onto the outward-occluded dDAT structure (4M48; Penmatsa et al., 
2013). Secondary structure predictions were used to increase accuracy of the sequence 
alignment, with a large unstructured region of EL2 (residues W315-Q362), N-terminus and C-
terminus removed from the model. Unrestrained molecular dynamic (MD) simulations were 
run for 50 ns (Subramanian et al., 2016) and the resulting RMSD was within expected thermal 
fluctuations (backbone RMSD 1.37 Å). Furthermore, the glycine substrate and Na+ ions remain 
coordinated by residues throughout simulations, suggesting the GlyT2 model is stable. 
 
Figure 1.9. Homology model of GlyT2 shown in plane of the membrane A. front face and 
B. reverse face. Important helices and loops are coloured, EL4 (orange), TM1 (red), TM3 
(blue), TM5 (yellow), TM7 (purple), and TM8 (teal). Model is based on outward-occluded dDAT 
(PDB: 4M48) using a protein fold recognition (or threading) approach. Model created by 
Nandhitha Subramanian. 
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This model has been used to identify a novel third Na+ binding site (Na3) in GlyT2 which is 
coordinated by residues in TM3 (W263, M276), TM6 (A481), and TM10 (E648) (Subramanian 
et al., 2016). Additionally, the specificity of the GlyT2 substrate binding site has been explored 
using functional data and MD using this model, which shows the primary binding site of GlyT2 
is unable to accommodate any other amino acids but the smallest amino acid, glycine (Carland 
et al., 2018). Simulations of GlyT2 are conducted in a typical 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) bilayer with 20% cholesterol to mimic the mammalian neuronal cell 
membrane. 
1.7 Lipid interactions with membrane proteins 
1.7.1 Living in the membrane environment 
The mammalian cell is compartmentalised by a lipid bilayer which acts to separate the 
chemistry of each cell from the external environment. Glycerophospholipids comprise majority 
of the mammalian cell membrane with the most abundant lipid, phosphatidylcholine, 
composing ~50%, and the remainder contributed by other phospholipids, sphingolipids, and 
accessory lipids such as cholesterol and cardiolipin (van Meer et al., 2008). Phospholipids are 
amphipathic molecules which self-assemble into a bilayer with their fatty acyl chains extending 
towards each other and their polar head groups facing the aqueous space. The final 
composition of the membrane can influence membrane curvature, liquid:gel phases, and can 
accommodate membrane proteins and modulate their activity. 
Interactions between proteins and lipid membranes range from non-selective annular lipid 
contacts which encircle a membrane protein, to highly selective lipid binding essential for 
function (Landreh et al., 2016). However, there are challenges in observing proteins in a more 
native, membrane-dissolved state, which has limited our understanding. The bacterial 
aquaporin has been crystallised at 1.9 Å with a full band of annular membrane lipids 
surrounding the protein (Gonen et al., 2005). Flexible acyl tails were observed to contour 
around the gaps and grooves of the protein structure, but did not occupy any tight lipid binding 
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sites, which suggests that this structure is a typical representation of how membrane lipids 
may interact with their protein residents. Furthermore, MD studies of this protein structure in 
a dimyristoyl-phosphocholine bilayer, shows constant exchange of membrane lipids for these 
protein grooves, and that the acyl tails governed the positioning of lipids around the channel, 
but that aquaporin did not possess any specific phospholipid binding sites (Aponte-Santamaria 
et al., 2012). Despite this, protein mobility greatly influenced the localisation of lipids around 
aquaporin which suggests that even non-selective lipid interactions may be significant for 
functioning of membrane proteins. 
Both proteins and lipids undergo structural changes with respect to each other which can affect 
their organisation within membranes. In particular, hydrophobic matching to minimise 
hydrophobic areas of a protein exposed to the aqueous environment is a strong driver of lipid-
protein dynamics (Harroun et al., 1999a, 1999b). Often hydrophobic portions of 
transmembrane helices do not match up with typical membrane thickness (30 Å, van Meer, 
2008). This hydrophobic mismatch can change between different protein conformations, and 
therefore a membrane must be dynamic when accommodating a flexible protein, as in the 
case of a transporter moving through the different conformations of a transport cycle. LeuT 
has been crystallised in a number of conformations which represent movements from an 
outward-open to an inward-open state (Yamashita et al., 2005; Krishnamurthy & Gouaux 
2012). Continuum MD allows the energetics of hydrophobic mismatch to be quantified in an 
elastic membrane, and has been used to monitor LeuT in a phospholipid membrane (Mondal 
et al., 2013). Differences in hydrophobic mismatch for different conformations of LeuT were 
observed, in addition to significant membrane thinning and water penetration near a 
membrane exposed, positively charged residue, K288 (Mondal et al., 2013). Neutralisation of 
this residue (K288A) yields a faster transporter, likely as a direct consequence of removing 
unfavourable interactions between K288 and the membrane.  Exposure to the lipid 
environment can either be favourable or unfavourable, and is clearly functionally relevant for 
the conformational changes required for membrane proteins. 
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One way to increase membrane protein stability is to form oligomeric interactions with other 
transmembrane subunits; the majority of membrane proteins are organised into higher order 
oligomers within the membrane environment. The role membrane lipids may have in stabilising 
oligomers has also been investigated using mass spectrometry to observe membrane proteins 
with a predicted weak oligomerisation interface (Gupta et al., 2017). LeuT for example, 
contains no salt bridges and little buried surface to drive oligomerisation, yet the mass 
spectrum of LeuT liberated from octylglucoside micelles shows a peak which corresponds to 
dimer formation (Gupta et al., 2017). In the absence of cardiolipin, however, LeuT forms a 
delipidated monomer, which suggests that dimerization between LeuT monomers is facilitated 
by cardiolipin “glue”, which can be knocked out using mutagenesis of the proposed interface.  
BetP is a trimeric betaine transporter from Corynebacterium glutamicum, with the same 
structural fold as LeuT (Koshy et al., 2013). The crystal structure of BetP at 2.7 Å revealed 8 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) lipids, 5 of which were non-
annular, resolved with the transporter. Many of these lipids were observed in the centre of the 
trimer and are thought to mediate oligomeric interactions. Additionally, the areas of the 
transporter in close contact with the lipids are areas of BetP which undergo considerable 
conformational changes for transport. The negatively charged head groups of POPG are 
closely interacting with loops important for gating (Koshy et al., 2013), and it is proposed that 
POPG may be a regulatory mechanism to control gating. This has since been supported 
through infrared spectroscopy of BetP reconstituted in two-dimensional crystals of negatively 
charged lipids (Güler et al., 2016). 
Other lipid molecules have also been proposed to modulate proteins via distinct interactions. 
The first crystal structure of the dopamine transporter, dDAT, revealed a cholesterol molecule 
coordinated in a membrane exposed cleft between TM1a, TM5, and TM7 (Figure 1.10, 
Penmatsa et al., 2013). The binding site of this cholesterol is comprised of largely branched 
aliphatic residues, which are conserved among many NSS transporters. Superimposition of 
the dDAT structure with the inward-open structure of LeuT reveals a potential regulatory 
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mechanism for cholesterol. For LeuT to enter the inward-open conformation and for substrate 
to be released, TM1a must shift into the membrane in the space occupied by cholesterol in 
the dDAT structure. Cholesterol may thus be an endogenous modulator of the dopamine 
transporter, favouring the outward-open conformation and preventing substrate release into 
the intracellular space. Increasing cholesterol content in membranes increases binding of 
cocaine analogues, which enter the central binding cavity in the outward-facing conformation 
(Hong & Amara, 2010). It has also recently been shown that cholesterol binding to the site 
identified in the dDAT structure inhibits the transition to an inward-facing conformation, for 
hDAT, hSERT, and the human noradrenalin transporter (Zeppelin et al., 2018). This specific 
cholesterol binding site may therefore be functionally relevant and conserved among the 
family. 
 
Figure 1.10. Cholesterol binding site of the dopamine transporter dDAT. Cholesterol 
(yellow sticks) is bound in a cleft between TM1a, TM5, and TM7. a. Binding site; residues that 
coordinate cholesterol are labelled and shown as sticks b. dDAT (coloured cartoon) 
superimposed with LeuT (grey cartoon) showing the relative movements of TM1a (Penmatsa 
et al., 2013). 
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While structural visualisation of membrane proteins in their native state remains challenging, 
it is clear that the membrane environment influences function, and is not merely a solvent for 
hydrophobic proteins. Emerging techniques such as cryo-electron microscopy (cryo-EM) of 
membrane proteins in nanodiscs (Efremov et al., 2017), detergent-free protein purification 
using styrene maleic acid polymers (Scheidelaar et al., 2015), and mass spectroscopy of 
membrane proteins liberated directly from lipid environments (Laganowsky et al., 2013), may 
provide more detailed and accurate information on membrane proteins and lipid interactions. 
1.7.2 Lipid ligands of membrane proteins 
In addition to protein interactions with the membrane environment, lipids have also been 
demonstrated to be endogenous ligands of a number of membrane proteins. Cannabinoid 
receptors (CB1 and CB2), the lysophosphatidic acid receptor (LPA), and the sphingosine-1-
phosphate receptor (S1P1) are members of the G protein-coupled receptor superfamily, which 
contain seven TM domains (Chrencik et al., 2015; Hanson et al., 2012; Hua et al., 2016; 
Taniguchi et al., 2017) and share moderate sequence identity, particularly around the 
membrane exposed TM helices. Each of these receptors are activated by lipid molecules with 
either a negatively charged, or neutral, head group conjugated to a long flexible acyl tail 
(Shimizu, 2009). These agonists contain similar features to the lipid inhibitors of GlyT2, with 
endogenous cannabinoids containing a polyunsaturated C20 tail similar to NAGly, and 
lysophosphatidic acid containing a monounsaturated C18 tail similar to NOGly. Crystal 
structures of G-protein coupled receptors, with molecular dynamics and modelling of 
endogenous substrates, can help to infer the mechanism of their lipid ligands and provide 
insight into lipid-protein binding. 
Arachidonylethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG) are the 
endogenous agonists of the cannabinoid receptors (Luchicchi & Pistis, 2012). They are highly 
lipophilic and therefore likely to exist within the membrane, where it has been hypothesised 
that they may access the binding site of CB receptors (Pei et al., 2008). Nuclear magnetic 
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resonance (NMR) spectroscopy of anandamide in a dipalmitoylphosphatidylcholine 
membrane reveals that although it could exist in a number of conformations, anandamide 
prefers to adopt an extended conformation within the membrane, with its head group next to 
neighbouring dipalmitoylphosphatidylcholine head groups and the terminal methyl adjacent to 
the terminal methyl of the phospholipid acyl chain (Tian et al., 2005). Molecular dynamics of 
2-AG binding to CB2 in a POPC bilayer observe the 2-AG lipid first associating with the 
membrane phospholipids, followed by migration of 2-AG to interact with the CB2 receptor 
(Hurst et al., 2010). 2-AG then enters the ligand binding site by moving through an opening 
between membrane exposed helices TM6 and TM7. Furthermore, the recent crystal structure 
of the inactive human CB1 receptor shows the synthetic antagonist, AM6538, bound in a 
membrane exposed pocket with its aliphatic chain substituted phenyl ring extending into a 
long hydrophobic channel of the receptor (Hua et al., 2016). Subsequent molecular docking 
of anandamide and 2-AG also show hydrophobic residues in TM2, TM3, TM6, and TM7 
interacting with the hydrophobic acyl tails in the predicted final binding site of these 
endogenous lipids. 
Similarly, the S1P1 structure bound to the sphingolipid mimic antagonist, ML056, reveals a 
highly amphipathic binding pocket which can accommodate the zwitterionic head group, and 
long acyl chain of spingosine-1-phosphate (Hanson et al., 2012). This binding site is occluded 
by an extracellular helical cap (Figure 1.11; Hanson et al., 2012) which suggests this site is 
not aqueously accessible. Instead, it is proposed that ligands enter laterally through a 
membrane exposed opening between helices TM1 and TM7. 
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Figure 1.11. Surface rendering of the sphingosine-1-phosphate crystal structure. Top-
down view showing the binding pocket occluded by the helical cap formed by extracellular 
loops ECL1, ECL2, ECL3 and the N-terminal helix. Side view showing the opening between 
membrane helices I and VII which may provide an access point through the lipid membrane 
(adapted from Hanson et al., 2012). 
 
Endogenous substrates of the free fatty acid receptor are saturated C12-C16 or unsaturated 
C18-C20 fatty acids, which act as full agonists (Kotarsky et al., 2003). In a crystal structure of 
the free fatty acid receptor, the partial agonist, TAK-875, is shown bound between helices 3 
and 4 whilst the substituted benzyl ring protrudes into the membrane (Srivastava et al., 2014). 
TAK-875 additionally possesses a ~380-fold preference for the lipophilic phase over the 
aqueous phase which suggests that it partitions into the lipid bilayer before interacting with 
free fatty acid receptor. It is notable that this site differs from the pocket observed for other 
GPCRs, and that access through helices via the membrane may be a ubiquitous pathway for 
lipid ligands. 
Transporters have also been identified to bind and transport lipids. The diversity of inner and 
outer membrane leaflets is maintained with unidirectional flippases, bidirectional scramblases, 
or phospholipid transporters (Montigny et al., 2016). Similarly, some bacteria utilise flippases 
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to transport bulky lipid molecules from their inner membrane, to the outer leaflet of the outer 
membrane (Mi et al., 2017). Translocation of lipids is often against a steep gradient and 
requires energetic coupling to either ATP hydrolysis or the transport of ions (Montigny et al., 
2016). Flippases and scramblases have very large phospholipid or lipopolysaccharide 
substrates which must be accommodated by large, flexible binding pockets and may provide 
insight into dynamic interactions of lipids with membrane proteins. 
For the bacterial lipopolysaccharide transporter, MsbA, a potential mechanism of flipping was 
postulated using cryo-EM structures bound to lipopolysaccharide and lipid A (Mi et al., 2017). 
In this model, the lipid is trapped in the inner core with the acyl chains accommodated by a 
large hydrophobic pocket before being flipped to the outer membrane. Conversely, for the 
scramblase-Ca2+ activated Cl- channel TMEM16, a different flipping mechanism was proposed 
where the head group traverses the membrane through a membrane exposed protein cavity 
while the acyl tails make contact with the bilayer (Brunner et al., 2014). In both cases, however, 
the lipids make contact with the membrane at some point during the transport cycle. 
In addition to endogenous substrates, lipids can also allosterically bind to specific sites on 
membrane proteins. Arachidonic acid has been observed to have a wide range of effects on 
ion channels, for example stimulating the inwardly rectifying K+ channel, Kir1.3 (Liu et al., 
2001), but inhibiting the voltage gated K+ channel, Kv1.5 (Bai et al., 2015). Arachidonic acid 
is also selective for Kir2.3 but has no activity on Kir2.1, Kir2.2, or Kir2.4; chimeras between 
subtypes show it directly interacts with transmembrane domains and is not simply disrupting 
the membrane to produce non-specific effects (Liu et al., 2001). The binding site of arachidonic 
acid on Kv1.5 has been mapped using site-directed mutagenesis and docking and reveals a 
site comprised of charged or polar residues interacting with the head, and a large number of 
branched aliphatic residues forming the tail binding site (Bai et al., 2015). 
It appears that for most lipid ligands of membrane proteins they must interact with both protein 
and lipid membrane, either navigating the bilayer to access their binding site, or binding at a 
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position that is comprised of both membrane and protein.  Between receptors, transporters, 
and channels there are conserved features of lipid binding sites; where the acyl tails fit in a 
large hydrophobic cavity comprised of branched aliphatic residues; and charged or polar 
amino acids forming the head group binding site. Despite the flexibility and large range of 
substrates, there are commonalities between known membrane-protein interactions which 
may provide insight into the mechanisms of lipid inhibition of glycine transporters. 
1.8 Development of lipids as drugs 
Drug discovery and development are often seen as being incompatible with lipids as they do 
not fit the guidelines for drug-likeness as defined by Lipinski’s rules, where permeability and 
absorption are optimal (for example; logP < 5; no more than 5 hydrogen bond donors; and a 
preference for small molecules with a molecular weight <500) (Lipinski et al., 1997). 
Additionally, lipids are abundantly present in cell membranes and possess roles as non-
specific signalling molecules, which often cause them to be overlooked for development as 
targeted therapies. 
Fingolimod is an orally available, first-in-class therapy to treat multiple sclerosis, which when 
phosphorylated in vivo, resembles sphingosine-1-phosphate and modulates four of the S1P 
receptors (Brinkmann et al., 2010). Fingolimod is able to traverse the BBB to accumulate in 
the CNS (Hunter et al., 2016). While fingolimod must then be phosphorylated to become active 
on central receptors, it is clear that the development of orally-available, lipid-based drugs is 
not unfeasible. 
CNS drugs must negotiate the BBB, either via passive diffusion (such as fingolimod) or 
through carrier mediated transport. For charged compounds, passage across the BBB occurs 
via active transport. ABC transporters, such as p-glycoprotein, and the breast cancer 
resistance protein can regulate the transport of a wide range of large, diverse species across 
the BBB (Uchida et al., 2011) and are known to participate in the flux of a number of CNS 
drugs. Organic cation and organic anion transporters are expressed in high amounts in the 
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human BBB (Uchida et al., 2011). Organic cation transporter 1 transports cationic compounds 
such as tetraethylammonium, and verapamil, while the high affinity Organic cation transporter 
2 transports zwitterionic carnitine (Yabuuchi et al., 1999) and has been shown to be important 
for acetyl-L-carnitine transport across the BBB (Inano et al., 2003). 
Anandamide is normally synthesised in the brain but has been shown to cross the BBB via a 
saturable uptake system (Maccarrone et al., 2005). Uptake is proposed to be via an 
endocannabinoid membrane transporter, which may provide a pathway for lipid ligands to 
rapidly accumulate. This transport system has not been identified and there remains some 
controversy as to its existence (Fowler, 2013); passive diffusion of uncharged anandamide is 
likely to contribute to BBB accumulation to some degree. 
Fatty acid transport into the brain is necessary to supply components for cell membranes and 
lipid precursors for fatty acids that cannot be synthesised in the brain. Fatty acid transport 
proteins, fatty acid binding proteins, and fatty acid translocase have been shown to be 
essential in the transport of long chain fatty acids across the BBB (Mitchell et al., 2011). There 
are many routes of passage for lipids into the CNS which may facilitate the movement of lipid-
based drugs. 
In addition to acyl-carnitines, acyl-glycines, endocannabinoids, and other lipid signalling 
molecules, there are believed to be a number of other bioactive lipids whose roles have not 
yet been elucidated. In 2010, a group began to identify the large number of endogenous lipids 
using nano-high performance liquid chromatography-tandem mass spectrometry, to identify 
and quantify acyl amino acids in the rat brain and bovine spinal cord (Tan et al., 2010). Tan 
and colleagues, identified 50 novel acyl amino acids with glutamic acid, serine, and palmitoyl 
conjugated compounds being most abundant. It was suggested the isolated species may 
reflect the populations of amino acids or precursor lipids available for synthesis in the brain. 
Lipids in the brain are also metabolised and recycled by a number of enzymes, including fatty 
acid amide hydrolase (FAAH) and cyclooxygenase (COX). FAAH inactivates fatty acid amide 
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compounds through hydrolysis of the L- amide bond and has been shown to have activity at 
anandamide and oleamide, converting each to arachidonic acid and oleic acid respectively 
(Cravatt et al., 1996). While FAAH is able to inactive head groups, tails can be metabolised 
through β-oxidation of the double bond, or cyclisation of the tail, for example COX-2 
inactivation of anandamide and NAGly (Prusakiewicz et al., 2002; Yu et al., 1997). Lipid 
compounds containing natural amino acids and unsaturated acyl tails have multiple routes of 
degradation which will need to be considered when designing lipid-based therapeutics. 
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Thesis objectives 
It is becoming increasingly apparent that lipids interact with membrane proteins through both 
non selective annular contacts and through specific binding sites, where they are able to 
greatly influence protein structure and function. While much is known about lipid ligand binding 
to G-protein coupled receptors, for transporters with the LeuT-like fold the extent that lipid 
interactions may impact function has only recently begun to be understood in depth. These 
interactions involve lipids within the natural membrane environment, whereas it is also known 
that the endogenous signalling lipid, NAGly, is able to bind to and inhibit the glycine 
transporter, GlyT2. The aims of this thesis were thus to elucidate important interactions that a 
group of synthesised acyl amino acid analogues have with GlyT2, and to describe the 
characteristics of these compounds for their use as specific, potent drugs in the treatment of 
chronic neuropathic pain. 
Targeting GlyT2 has proven difficult as it possesses an essential role in the repackaging and 
recycling of glycine. Many GlyT2 inhibitors which have been developed, block this recycling 
by acting as full and/or irreversible inhibitors and produce severe side effects which mimic 
GlyT2 knockout and hyperekplexic phenotypes. The first aim of this thesis was to develop a 
library of lipid compounds with different head and tail groups that possess different inhibitory 
characteristics, as well as improving upon the potency of NAGly (IC50 9 µM). Using two-
electrode voltage clamp electrophysiology and radiolabelled [3H]-glycine uptake I sought to 
determine the relative affinities (IC50 values), maximal levels of inhibition, and reversibility of a 
number of lipid compounds which were synthesised for this study. The pharmacokinetic and 
in vivo characteristics for select compounds are also described. 
A number of crystal structures of the bacterial homologue, LeuT, in different states have 
provided detail about different conformational transitions, which have since been described 
using biophysical techniques. EL4 is thought to undergo large conformational changes from 
the outward-open to the inward facing states and has also been shown to be important in the 
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mechanism of GlyT2 inhibition by NAGly. To further resolve the mechanism of inhibition, I 
created a number of GlyT2 mutations in regions that were either close to EL4 or also important 
in the mechanism of transport and may influence the way EL4 moves. Using site-directed 
mutagenesis and electrophysiology, I aimed to unearth molecular determinants for the binding 
of acyl amino acids and to further develop understanding of how these compounds can stall 
transport. 
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Chapter 2: Methods 
2.1 Materials 
N-arachidonyl glycine and N-oleoyl glycine were obtained from Sapphire Biosciences (NSW, 
Australia); and oleoyl L-carnitine was obtained from Larodan Fine Chemicals (Malmo, 
Sweden). All other N-acyl amino acids presented in this thesis were synthesised by Dr Tristan 
Rawling and Susan Shimmon at the University of Technology (Sydney, Australia). For 
compounds with typical acyl tails the fatty acid was obtained as a starting material, for 
example, oleic acid. To create compounds with non-commercially available monounsaturated 
fatty acids, the Wittig reaction was used to synthesise tails with different carbon lengths and 
double bonds, as previously described in Mostyn et al., 2017. Amide bonds between the amino 
acid head group and fatty acid tail were formed using a peptide coupling reagent. All other 
chemicals were obtained from Sigma Aldrich (Sydney, Australia), unless otherwise stated. 
2.2 Creation of wild type (WT) or mutant mRNA encoding glycine transporters 
Human GlyT1b or GlyT2a (herein referred to as GlyT1 and GlyT2) cDNA were sub-cloned into 
the plasmid oocyte transcription vector (pOTV). Site directed mutagenesis was performed 
using the Q5 site-directed mutagenesis kit (New England Biolabs (Genesearch), Arundel, 
Australia) using oligonucleotide primers synthesised by Sigma Aldrich (Sydney, Australia). 
PCR products were then transformed into E. coli cells and pure plasmid DNA extracted using 
the Purelink Quick Plasmid Miniprep Kit (Invitrogen by Life Technologies, Löhne, Germany). 
Sequences were confirmed by the Australian Genome Research Facility (Sydney, Australia). 
WT and mutant plasmid DNA were linearised with SpeI (New England Biolabs (Genesearch) 
Arundel, Australia) and RNA transcribed by T7 RNA polymerase using the 
mMessagemMachine kit (Ambion, TX, USA). 
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2.3 Harvesting and preparing oocytes 
An all-female Xenopus laevis colony were housed in shared tanks of no more than 3 tank-
mates, and kept at constant, comfortable conditions to maintain a healthy colony for year-
round production of oocytes, and to maintain a high quality of life in accordance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. The 
colony was kept on a 12 hour light/12 hour dark light cycle, in tanks of filtered 18 ºC  de-
chlorinated water, with water pH, hardness, nitrate levels, salinity, and O2/CO2 levels 
constantly monitored for water quality.  
Oocytes were extracted from female Xenopus laevis frogs anaesthetised with 0.17% 3-
aminbenzoic acid ethyl ester (tricaine).  A small incision was made in the abdomen to extract 
a lobe of oocytes. Oocytes were detached from follicle cell containing lobes by digestion with 
2 mg/mL collagenase A (Boehringer, Mannheim, Germany) at room temperature for 60-90 
minutes.  
Defoliculated stage V-VI oocytes were injected with 4.6 ng of cRNA encoding WT or mutant 
transporter (Drummond Nanoinject, Drummond Scientific Co., Broomall, PA, USA). The 
oocytes were stored at 16-18 ºC for 2-5 days in ND96 solution (96 mM NaCl, 2 mM KCL, 1 
mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.55), supplemented with 2.5 mM sodium 
pyruvate, 0.5 mM theophylline, 50 µg/mL gentamicin and 100 µM/mL tetracycline until 
transporter expression levels were sufficient to measure transporter function. 
2.4 Two electrode voltage clamp electrophysiology 
Glycine transport by GlyT2 is coupled to 3 Na+ ions and 1 Cl-, which creates an electrogenic 
process that allows two electrode voltage clamp electrophysiology to be used to measure 
glycine transport (Figure 2.1). 2-5 days following injection, glycine transport currents were 
measured at -60 mV using Geneclamp 500 amplifier (Axon Instruments, Foster City, CA, USA) 
with a Powerlab 2/20 chart recorder (ADInstruments, Sydney, Australia) and chart software 
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(ADInstruments). All data was subsequently analysed using GraphPad Prism 7.02 (GraphPad 
Software, San Diego, CA). 
Figure 2.1. Setup of two-electrode voltage clamp electrophysiology. Xenopus laevis 
oocytes expressing GlyT2 (orange sectors) sit in a recording bath with ND96 (reference 
recording solution) penetrated by two Ag/AgCl2 microelectrodes; the voltage electrode and the 
current electrode. The Ag/AgCl2 ground electrode is placed in the recording bath and voltage 
and current electrodes referenced to the recording solution prior to setup. The voltage 
electrode measures membrane potential, and the amplifier “Amp” is compared to the set 
command voltage (-60 mV for GlyT2). Any differences are corrected by the “Feedback amp” 
and current is injected into the oocyte via the current electrode to adjust the membrane 
potential. Currents across the cell membrane are monitored using a current-to-voltage 
converter providing an amplified output of membrane current (I), indicative of glycine transport.  
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2.4.1 Glycine concentration responses 
Initially, the function of each mutant transporter was tested by measuring glycine concentration 
dependent transport currents in ND96 (96 mM Na+) to drive transport. EC50 values were 
determined using the modified Michaelis-Menten equation: 
I = ([Gly].Imax)/EC50 + [Gly])  [Equation 1] 
where I is current (nA), [Gly] is the concentration of glycine, Imax is the current generated by a 
maximal concentration of glycine (300 µM) and EC50 is the concentration of glycine that 
generates a half maximal current.  Values are presented as mean ± SEM obtained from  
n ≥ 3 cells from at least two batches of oocytes. To determine if mutations affected glycine 
transport, one way ANOVA tests were employed, with a Dunnett’s post-hoc test used for 
comparison with WT GlyT2. For comparison with WT GlyT1 a two-tailed t-test was used. 
Statistical significance were represented as p < 0.05 *, p < 0.01 **, p < 0.001 *** etc. in the 
following figures. 
2.4.2 Critical micelle concentrations of acyl amino acids  
The synthesised lipids are amphipathic with a hydrophobic tail and a polar head group and 
have the propensity to spontaneously form micelles in solution at a characteristic critical 
micelle concentration (CMC). Thus, concentrations of lipids higher than the CMC may not 
freely diffuse to interact with proteins and thereby limit their biological activity. The CMC for 
OLCarn is approximately 7 μM (Carland et al., 2013) and for NAGly is 100 μM (Wiles et al., 
2006). It’s also similarly been shown that larger oleic based surfactants with an imidazole ring 
have a CMC of >10 μM (Bhadani et al., 2017). For acyl-glycine compounds the maximum 
concentration used was limited to 30 μM. It should be noted that for NAGly, a true plateau of 
inhibition was not reached for concentrations below its CMC. Curve fitting of this partial 
concentration response predicts full inhibition at higher concentrations. In the case of NAGly, 
the solubility of the compound could be limiting the level of inhibition reached in both in vitro 
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and in vivo assays. For N-acyl amino acids with larger head groups, the maximum 
concentration used was limited to 3 μM for positively charged head groups or 10 μM for others. 
2.4.3 Acyl inhibitor concentration responses 
The majority of N-acyl amino acids are not immediately reversible, and thus inhibitor 
concentration responses were performed using cumulative application. The EC50 
concentration of glycine was applied until a stable level of transport was reached. Increasing 
concentrations of N-acyl amino acid were then co-applied with glycine, with each 
concentration producing a distinct plateau in response. Currents at each of these plateaus 
were measured and compared to glycine currents in the absence of any inhibitor. 
Inhibitor concentration responses were then fit by the method of least squares using: 
Y=Bottom + (Top-Bottom)/(1+10(X-LogIC50))  [Equation 2] 
where X is log[acyl amino acid] (µM), Y is current normalised to glycine in the absence of 
inhibitor and Top and Bottom are the maximal and minimal plateau responses respectively. 
This equation was constrained to have the bottom value > 0, but not = 0, as to capture partial 
levels of inhibition, and the standard hill slope -1.0. Concentration response curves were thus 
able to generate IC50 values as well as % maximum (max.) inhibition values. 
IC50 values are presented as mean and 95% confidence intervals, and % max inhibition are 
presented as mean ± SEM. Data are from n ≥ 3 cells from at least two batches of oocytes. 
Where significant inhibition was not reached, the IC50 value is recorded as greater than the 
highest concentration of N-acyl amino acid used. For mutant inhibitor concentration 
responses, one way ANOVA tests with Dunnett’s post-hoc tests for comparison with WT GlyT2 
were performed, for both IC50 and % max. inhibition values, and presented as p < 0.05 *, p < 
0.01 **, p < 0.001 *** etc. in Table 5.2.  
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2.4.4 Acyl inhibitor washout time course 
In addition to apparent affinity and % max. inhibition, acyl inhibitors also possess a 
characteristic reversibility. Reversibility was determined by a washout time course using the 
IC50 concentration of each compound. Glycine (EC50) was applied, followed by co-application 
of glycine and inhibitor until stable inhibition was reached. Application of inhibitor was ceased 
(time 0) and ND96 buffer was then perfused into the recording bath to wash the oocyte. At 5 
minute intervals the EC50 concentration of glycine was reapplied to measure transport 
recovery. Recovery was expressed as I/Imax, where Imax is the current produced by glycine in 
the absence of inhibitor. 
2.4.5 Oleoyl L-Lys competition assay 
Glycine concentration responses were performed on oocytes expressing GlyT2 first in the 
absence of inhibitor, and then in the presence of 10 nM, 30 nM, or 1 µM oleoyl L-Lys. Oleoyl 
L-Lys is not immediately reversible so glycine concentration responses were generated by first 
applying ND96 with oleoyl L-Lys for 2 minutes and then adding increasing concentrations of 
glycine and measuring the plateau response for each value. Currents were normalised to the 
Imax at the maximal glycine concentration (300 µM) in the absence of inhibitor for each 
individual cell. EC50 values were determined using Equation 1. Data was then transformed 
using an Eadie-Hofstee plot. One way ANOVA analysis with Dunnett’s post-hoc tests were 
performed for both EC50 and Imax values, and presented as p < 0.05 *, p < 0.01 **, p < 0.001 
*** etc. 
2.5 Radiolabelled uptake 
2.5.1 [3H]-Glycine uptake time course 
Oocytes expressing GlyT2 as well as uninjected controls were pre-incubated with 3 μM acyl-
glycine lipids for 2 minutes, incubated with 10 μM [3H]-glycine for 0.5, 1, 2, 5, and 10 minutes, 
and then washed 3 times in ice cold ND96. Oocytes were then placed in 0.1 M NaOH for 30 
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minutes to lyse the oocytes. Scintillant was added, and the [3H] counted in a Trilux beta 
counter. The rate of uptake was estimated by fitting the linear portion of the time course to a 
straight line.  
2.5.1 [3H]-Glycine uptake on oocytes expressing GlyT1 and GlyT2 
Oocytes expressing GlyT2 or GlyT1 and uninjected controls were pre-incubated with 100 nM 
or 1 μM oleoyl L-Lys for 2 minutes at room temperature and then incubated with 10 μM [3H]-
glycine for a further 2 minutes. Oocytes were then washed 3 times in ice cold ND96 and lysed 
with 0.1 M NaOH for 30 minutes. Scintillant was added to vials and the [3H] counted using a 
Trilux beta counter. Background [3H]-glycine uptake by uninjected controls was subtracted, 
and total counts were normalised to the uptake of [3H]-glycine by GlyT2 or GlyT1 in the 
absence of inhibitor. 
2.6 Pharmacokinetics of oleoyl L-Lys and oleoyl D-Lys 
The following experiments were conducted by the Centre for Drug Candidate Optimisation 
(CDCO) at Monash University (Victoria, Australia). 
2.6.1 Stability in plasma and liver microsomes 
Rat plasma or liver microsomes from male Sprague Dawley rats were spiked with solutions of 
either oleoyl L-Lys or oleoyl D-Lys. At various time points over the 240 minutes (plasma) or 60 
minutes (liver microsome) incubation period, samples were taken and analysed using liquid 
chromatography mass spectrometry (LC/MS). 
2.6.2 Blood brain barrier permeability 
27.5 mg/kg oleoyl D-Lys was administered to male Sprague Dawley rats as a bolus injection 
into the peritoneal cavity at 5 mL/kg suspended in 10% (v/v) DMSO in 1% Solutol in 50 mM 
PBS 7.4. Plasma was collected before administration and then 1, 2, 4, 6, and 24 hr following 
administration. Standard calculations for each pharmacokinetic parameter are listed below.  
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t1/2 = ln(2)/ λz 
Where t = t1/2 is the elimination half-life and λz is the terminal elimination rate constant after 
intraperitoneal administration. AUC is the area under the plasma concentration versus time 
profile after IP administration, Cmax is the maximum plasma concentration observed after IP 
administration, and Tmax is the time to achieve Cmax. 
2.7 Analgesia testing in a partial nerve ligation model of pain 
Male Sprague Dawley rats were anaesthetised, an incision was made at the approximate level 
of the sciatic nerve, and the nerve was exposed by blunt dissection. The sciatic nerve was 
isolated from the surrounding fascia, and approximately 1/3-1/2 of the dorsal nerve was ligated 
with a suture. The wound was closed and sensory signs of allodynia and hyperalgesia 
developed over 7-14 days. The Von Frey assay was used to measure nociception prior to 
surgery, after surgery, and at various time points following intraperitoneal injection of either 3 
mg/kg (low dose) or 30 mg/kg (high dose) oleoyl D-Lys. Nylon filaments of varying diameters 
were applied to the rat’s hindpaw, and paw withdrawal was observed at each condition. 
Analgesia experiments were carried out by Dr Sarasa Mohammadi (University of Sydney, 
Australia). 
2.8 GlyT2 homology model and docking of lipid inhibitors 
The GlyT2 homology model was created using the outward-occluded dopamine transporter 
structure from Drosophila melanogaster (dDAT) (PDB: 4M48) as a template using a threading 
approach implemented in the Phyre2 webserver. A sequence alignment of NSS transporters 
was performed, with GlyT2 sharing 50% identity with dDAT. The model was further refined 
using secondary structure prediction and alteration of protonation states of ionisable side 
chains. GlyT2 was then solvated and equilibrated in a POPC bilayer. After 41 nanoseconds of 
simulation, the representative structure of GlyT2 was obtained (methods described in further 
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detail in Subramanian et al., 2016). The GlyT2 homology model was created by Dr Nandhitha 
Subramanian (Australian National University). 
Docking of oleoyl D-Lys onto GlyT2 was performed using AutoDock Vina, a program that 
obtains energetically favourable binding conformations of a ligand by scoring binding 
conformations (scoring function and methods described in more detail in Trott & Olson, 2010). 
Majority of protein was static, while Ile545, Tyr550, Trp563, Pro561, Phe428, Leu569, and 
Phe515 residues were allowed to freely rotate about flexible bonds. Oleoyl D-Lys was also 
permitted to freely rotate. Docking simulations were performed by Mitchell Blyth (Australian 
National University).  
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Chapter 3: Characterisation of novel acyl-glycine inhibitors of GlyT2 
The work presented in this chapter has been published in ACS Chemical Neuroscience. 
Mostyn SN, Carland JE, Shimmon S, Ryan R, Rawling T, Vandenberg RJ (2017) Synthesis 
and characterisation of novel acyl-glycine inhibitors of GlyT2, ACS Chemical Neuroscience, 
8, 1949-1959 
3.1 Introduction 
N-arachidonyl glycine (NAGly) is an endogenous amino acid-conjugated lipid, derived from 
the well characterised bioactive lipid, anandamide. It is produced in its greatest quantities in 
the spinal cord, an important area for the dispatch of sensory signalling, and may have a role 
in the regulation of pain signalling. Intrathecal injection of NAGly has been shown to reduce 
mechanical allodynia and thermal hyperalgesia in rat models of both neuropathic and 
inflammatory chronic pain (Succar et al., 2007; Vuong et al., 2008). Furthermore, co-
application of NAGly with CB1 or CB2 receptor antagonists does not disrupt the analgesic 
effects of NAGly which is consistent with early binding studies of anandamide derivatives that 
show NAGly has negligible activity at cannabinoid receptors (Sheskin et al., 1997), which 
raises the question as to how NAGly mediates its analgesic activity. One possible mechanism 
of action is modulation of glycinergic neurotransmission. NAGly prolongs the time course of 
glycine in glycinergic synapses of lamina II of the superficial dorsal horn (Jeong et al., 2010), 
an area responsible for integrating ascending pain information. It has been shown that NAGly 
inhibits the glycine transporter GlyT2, but has no effect on the closely related glycine 
transporter GlyT1 (Wiles et al., 2006), which suggests that NAGly may exert analgesia by 
increasing inhibitory tone at glycinergic synapses.  
GlyT2 is an essential protein; knock out of the GlyT2 gene in mice produces severe 
neuromotor symptoms and is lethal 2 weeks postnatal (Gomeza et al., 2003b). The 
consequences of this deletion are presynaptic in origin, which suggests GlyT2 plays a crucial 
role in maintaining the pool of glycine to be loaded into vesicles for exocytotic release.  
- 48 - 
 
ORG-25543 is a full and irreversible GlyT2 inhibitor which also exhibits an excitotoxic 
phenotype that may mimic GlyT2 knock out effects, and is likely a result of disrupted vesicle 
filling and therefore a decrease in glycine in the synapse in the long term (Mingorance-Le Meur 
et al., 2013; Vandenberg et al., 2016). Conversely, partial reduction in GlyT2 expression using 
siRNA does not produce the hyperekplexia like symptoms generated by GlyT2 knock outs or 
full inhibitors. Additionally, targeted partial knock down of GlyT2 has been shown to be 
analgesic in neuropathic pain models in mice (Morita et al., 2008), validating the value of partial 
inhibitors of GlyT2. Partial, non-competitive glycine transport inhibitors are likely to slow the 
clearance rate of glycine from the synapse, but not block it completely, and thereby still allow 
accumulation of presynaptic glycine that is sufficient for recycling. NAGly is also a partial, non-
competitive inhibitor of GlyT2 and does not generate any overt motor side effects (Succar et 
al., 2007; Vuong et al., 2008), suggesting that compounds like NAGly have potential for the 
treatment of pain with minimal side effects.  
Although exogenous NAGly has been shown to be efficacious for the treatment of pain, its 
utility is limited by its rapid metabolism (Prusakiewicz et al., 2002), low potency at GlyT2 (IC50 
9 μM, Wiles et al., 2006), and role as a nonspecific signalling molecule (Huang et al., 2001; 
Prusakiewicz et al., 2002). COX-2 is present in high concentrations in tissues rich in NAGly 
and inactivates the molecule through a cyclization reaction at its ω6 polyunsaturated 
arachidonyl tail (Prusakiewicz et al., 2002). One strategy to circumvent, or slow, the 
metabolism of a GlyT2 lipid inhibitor is to alter the lipid tail of the compound. Previously, our 
group has reported the activity of N-oleoyl glycine (NOGly) as an inhibitor of GlyT2 (Carland 
et al., 2013). NOGly similarly contains a glycine head group and has instead an ω9 
monounsaturated 18-carbon tail (Figure 3.2) which imparts a lower maximal level of inhibition 
at GlyT2 and may provide important clues for the future development of partial inhibitors.  
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Figure 3.1. Structures of NAGly and NOGly. A. N-arachidonyl glycine (NAGly) (compound 
1) and B. N-oleoyl glycine (NOGly) (compound 2) 
 
It has been reported that compounds containing saturated or polyunsaturated tails are either 
inactive or have a much lower potency (Carland et al., 2013). This is in contrast to N-acyl 
ethanolamine derivatives of anandamide where 3 or 4 double bonds were required to impart 
significant activity at CB receptors (Lin et al., 1998; Sheskin et al., 1997; Thomas et al., 1996). 
The tail group of the compounds contributes to the mechanism of inhibition, but the extent of 
its influence is unknown. In this chapter I report the activity of synthesised glycine conjugated 
monounsaturated 14, 16, or 18 carbon lipids and their potency in inhibiting glycine transport 
by GlyT2 and the closely related GlyT1 transporter. 
3.2 Results and Discussion 
NOGly (Figure 3.1) is comprised of a glycine head group covalently bonded to an 18 carbon 
monounsaturated fatty acid (MUFA) tail bearing an ω9 cis-double bond (referred to as C18 
ω9 gly). To examine the influence of double bond position on GlyT2 inhibition, a series of 
NOGly analogues were synthesized by Dr Tristan Rawling (UTS), in which the alkene bond 
was moved to the ω11, ω7, ω5, or ω3 position. Analogues with ω12 and ω6 double bonds 
were also prepared, which are common motifs in natural fatty acids, as well as both cis and 
trans isomers. In addition, acyl-glycine compounds with 14 and 16 carbon MUFA tails were 
synthesized to assess the impact of chain length on potency. 
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3.2.1 Inhibitory activity of acyl-glycine analogues at GlyT2 and GlyT1 
Glycine transport by GlyT2 and GlyT1 is coupled to the cotransport of 3Na+/1Cl− and 2Na+/1Cl− 
respectively (Roux & Supplisson, 2000), creating an electrogenic process that can be 
measured electrophysiological techniques. Application of glycine to Xenopus laevis oocytes 
expressing GlyT2, clamped at −60 mV, results in inward currents with an EC50 of 21.6 ± 1.6 
μM, which is consistent with previously reported values (Vandenberg et al., 2007). The 
inhibitory profiles of each of the synthesized compounds was assayed by measuring glycine 
dependent (EC50) currents in the presence of increasing concentrations of lipid to determine 
IC50 values at GlyT2 and GlyT1. NAGly (1) and NOGly (2) have previously been shown to be 
non-transportable, non-competitive inhibitors of GlyT2 with little or no activity on GlyT1 
(Carland et al., 2013; Edington et al., 2009; Wiles et al., 2006). The newly synthesized acyl-
glycine analogues do not generate currents when applied to oocytes at concentrations up to 
10 μM for 5 minutes, which are conditions that lead to a substantial destabilising inward current 
when 3 μM oleoyl L-carnitine (OLCarn) is applied (Carland et al., 2013). The lack of any acyl-
glycine induced current suggests that these compounds are not substrates for the transporter 
and also that the compounds are unlikely to induce any chaotropic effects on the cell 
membrane.  
Application of the EC50 concentration of glycine produced robust inward currents (Figure 3.2), 
which were reduced in the presence of lipid inhibitors (representative current traces are shown 
for C16 ω6 Gly (15) and C18 ω8 Gly (7) inhibition of glycine transport). Following inhibition, 
glycine and inhibitor were washed from the bath by continuously perfusing ND96 buffer over 
the oocyte. Reapplication of glycine 5 minutes post-inhibition results in currents comparable 
to pre-exposure glycine transport currents, indicating that binding of the inhibitors is reversible. 
Concentration inhibition curves were generated for each compound with the max inhibition, 
and relative IC50 values at GlyT2 and GlyT1 presented in Table 3.1. While many compounds 
showed marked inhibition of transport by GlyT2, none of the compounds tested showed any 
appreciable inhibitory activity on the closely related glycine transporter GlyT1. 
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Figure 3.2. Example glycine induced transport current traces from oocytes expressing 
GlyT2 and clamped at -60 mV. The EC50 of glycine was applied (open bars) and produced 
inward currents which were inhibited (closed bars) by A. 1 µM C16 ω6 Gly (15) and B. 1 µM 
C18 ω8 Gly (7). 5 minutes following inhibition the EC50 of glycine was reapplied to show 
reversibility of inhibition and restoration of glycine currents to pre-exposure levels. 
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3.2.2 Activity of C18 acyl-glycine analogues 
Maintaining the 18-carbon chain and positioning the double bond more than two bonds from 
the ω9 position (in compounds ω3-ω7 (3-6), ω11 (9), and ω12 (10)), produced inactive 
compounds. To further probe this apparent strict requirement for double bond position we 
synthesized C18 ω8 Gly (7) and C18 ω10 Gly (8), in which the double bond is shifted by only 
one bond. Both analogues had slightly increased potencies compared to NOGly (0.32 μM for 
ω8 and 0.34 μM for ω10 compared to 0.50 μM for NOGly). It is notable that shifting the position 
of the double bond by one further carbon (C18 ω7 (6) or C18 ω11 (9)) to either end of the lipid 
chain abolished inhibitory activity (Figure 3.3A). For the C18-compounds, it is apparent that 
compounds with double bonds in this “goldilocks zone” are selective for GlyT2. It is also 
notable that these analogues are partial inhibitors of GlyT2, with the maximal level of inhibition 
observed being 52−66% (Table 3.1). Flexible monounsaturated lipids can exist in a number 
of different conformations. If the tail is not directly interacting with GlyT2, and instead sticking 
in the membrane or adjacent to hydrophobic regions of the transporter, a large number of 
subtle binding positions could be accommodated. To further probe the importance of the 
double bond, trans-isomers of the ω7 and ω9 C18- compounds were synthesized and 
screened on GlyT2 and GlyT1. The minimum energy conformation of a hydrocarbon tail with 
a cis double bond approximately medial has a substantial kink, which has been shown to 
distort the packing of membrane lipids (Funari et al., 2003). However, trans double bonds 
would constrain the geometry of the tail to adopt a similar conformation as saturated lipids, 
which have been previously shown to be inactive at GlyT2 (Carland et al., 2013). In contrast 
to the cis-isomers, C18 trans-ω9 gly (12) and C18 trans-ω7 gly (11) were both inactive (Figure 
3.3C) which suggests there is a selective pocket on GlyT2 which can only accommodate cis 
conformations of the lipid tail moiety. 
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Figure 3.3. Monounsaturated C18 acyl-glycines inhibit glycine transport currents of 
GlyT2 and GlyT1 transporters expressed in Xenopus laevis oocytes. 30 μM glycine 
transport currents were measured in the presence of lipids in the range of 10 nM to 10 μM for 
A. GlyT2 and B. GlyT1. C. Concentration-dependent inhibition of GlyT2 and GlyT1 for 
compounds (11) and (12). The responses are normalized mean values ± SEM (n ≥ 3 cells) fit 
using least-squares analysis. 
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3.2.3 Activity of C16 and C14 acyl-glycine analogues 
Substitution of the lipid tail in NAGly with C16-MUFAs and a double bond at any of the ω3, 
ω5, ω6, ω7, ω9, ω11, or ω12 positions, produced compounds which were active at GlyT2 
with IC50 values ranging from 0.81 to 3.5 μM (Figure 3.4). As can be seen by the % max 
inhibition (Table 3.1), a majority of the C16 compounds inhibited glycine transport currents to 
a greater extent than previously reported [partial] lipid inhibitors of GlyT2. C16 compounds 
with double bonds in the ω5 through ω11 positions inhibited GlyT2 in the range of 85−98% 
(Table 3.1). Shortening the chain also appeared to reduce the affinity of the acyl-glycines (C14 
ω5 Gly IC50 9.2 μM). 
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Figure 3.4. Monounsaturated C16 and C14 acyl-glycines inhibit glycine transport 
currents of GlyT2 and GlyT1 transporters expressed in Xenopus laevis oocytes. 30 μM 
glycine transport currents were measured in the presence of lipids in the range of 10 nM to 30 
μM. A. Concentration–inhibition curves for partial inhibitors (compounds 13 and 19) on GlyT2. 
B. Concentration–inhibition curves for full inhibitors (compounds 14–18 and 20) on GlyT2. C. 
Concentration-dependent effects of compounds (13–20) on glycine transport currents of 
GlyT1. The responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares 
analysis.  
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Table 3.1. Structure-activity relationships of C14, C16, and C18 glycine 
compounds at GlyT2 and GlyT1 
Compounds were tested for inhibition of 30 µM glycine transport by GlyT2 and GlyT1, 
expressed in Xenopus laevis oocytes. n ≥ 3 with measurements taken from at least 2 batches 
of oocytes. Data presented are mean and 95 % confidence intervals or mean ± SEM.   
aCompounds are commercially available and have been previously described as GlyT2 
inhibitors. bWhere significant inhibition was not reached, IC50 are presented as greater than 
the maximum concentration of each compound applied.  
cWhere a plateau in concentration-inhibition did not occur at the maximal concentration used 
the % max response given is the inhibition at the max concentration. 
 
  
 
IC50 (µM) (95% CI) % max 
Inhibition of 
GlyT2c GlyT2a GlyT1b 
Compound R 
1 
NAGlya 
C20 cis 
ω6,9,12,15 
9.1 
(4.5-18) >10
b 79.6 ± 2.1 
2 
NOGlya C18 cis ω9 
0.50 
(0.23-1.1) >10 66.8 ± 2.8 
3 C18 cis ω3 >10 >10 - 
4 C18 cis ω5 >10 >10 - 
5 C18 cis ω6 >10 >10 - 
6 C18 cis ω7 >10 >10 - 
7 C18 cis ω8 0.32 (0.18-0.57) >10 61.3 ± 1.7 
8 C18 cis ω10 0.34 (0.14-0.84) >10 52.4 ± 2.2 
9 C18 cis ω11 >10 >10 - 
10 C18 cis ω12 >10 >10 - 
11 C18 trans ω7 >10 >10 - 
12 C18 trans ω9 >10 >10 - 
13 C16 cis ω3 0.81 (0.46-1.4) >10 65.3 ± 1.9 
14 C16 cis ω5 3.5 (2.8-4.4) >10 92.3 ± 2.1 
15 C16 cis ω6 1.7 (1.4-2.2) >10 85.2 ± 1.0 
16 C16 cis ω7 1.5 (1.3-1.8) >10 92.5 ± 1.6 
17 C16 cis ω9 3.2 (2.7-3.9) >10 88.2 ± 2.6 
18 C16 cis ω11 3.4 (2.5-4.8) >10 97.9 ± 2.3 
19 C16 cis ω12 0.93 (0.41-2.2) >10 48.5 ± 1.4 
20 C14 cis ω5 9.2 (7.3-12) >10 100 ± 7.2 
R
NH
O
O
- 57 - 
 
3.2.4 C18 ꞷ8 gly and C16 ꞷ6 gly inhibit [3H]-glycine uptake by oocytes 
expressing GlyT2 
While it has been previously demonstrated that glycine-induced currents are directly related 
to the rate of glycine transport, I also examined the effect of representative lipids on the rate 
of [3H]-glycine uptake by oocytes expressing GlyT2. A time course of [3H]-glycine uptake was 
measured in the absence of inhibitors and in the presence of 10 μM C18 ω8 Gly and 10 μM 
C16 ω6 Gly. Both lipids caused ∼50% reductions in the rate of [3H]-glycine transport over 10 
minutes (Figure 3.5), which is comparable to the effects observed for inhibition of glycine 
transport currents. It is notable that uninjected oocytes allowed ∼15% of uptake compared to 
oocytes expressing GlyT2 and that this background level of uptake was not affected by the 
acyl-glycines. Thus, low levels of transport are likely due to an unrelated endogenous Xenopus 
oocyte amino acid transporter, which was not inhibited by acyl-glycine compounds. 
Additionally, the lack of any substantial change in the rate of background [3H]-glycine uptake 
also confirms that there is minimal, if any, chaotropic effects of the lipids on the cell membrane. 
 
 
Figure 3.5. Rates of [3H]-glycine uptake in the presence and absence of acyl-glycine 
inhibitors. Oocytes expressing GlyT2 and uninjected control oocytes were pre-incubated with 
10 μM C16 ω6 Gly, 10 μM C18 ω8 Gly, or buffer for 2 minutes, and then the rate of 10 μM 
[3H]-glycine transport measured as described in the Methods. 
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3.2.5 There is a preferred double bond position and chain length for conferring 
affinity and extent of inhibition 
It appears that when the double bond is in the centre of the carbon chain, the inhibitors are 
active (in the case of C18) or show a greater level of maximal inhibition (in the case of C16). 
However, as the properties imparted by a medial double bond differ between C16 and C18 
compounds it cannot be ascertained whether the trend is connected. The order of potency 
was C18 > C16 > C14 for the monounsaturated compounds tested, which suggests tail length 
is governing activity of the inhibitors. While C18 compounds were the most potent, the 
placement of the double bond within the tail was limited to a stringently defined zone in the 
middle of the chain (from ω8-10). The lower affinity C14 and C16 compounds were all active 
as GlyT2 inhibitors, with generally increased maximal level of inhibition. While the C18 
compounds are more potent than their C16 counterparts, the maximal level of inhibition was 
reduced (52−67% for C18 ω8, ω9, ω10 and 88−92% for C16 ω5, ω6, ω7, ω9, ω11). I 
speculate that there is an optimal size and/or shape of the lipid tail which can be 
accommodated in the allosteric inhibitor binding pocket. While lipids with C14, C16, and C18 
tails with glycine head group can fit into a binding pocket, lipids with larger C18 tails are likely 
to have the potential to form more hydrophobic interactions causing increased potency of 
inhibition, but also creating partial inhibitors. In the case of NAGly, its C20 polyunsaturated tail 
would be more condensed than the shorter monounsaturated lipids, allowing it to fit in the lipid 
binding site. The observed lower affinity of NAGly could be due to the number of kinks in the 
tail which restrict the ideal binding mode and reduce the capacity for intermolecular 
interactions. For inactive C18 acyl-glycine compounds, the cis double bond would create 
lateral kinks which may not be accommodated if the acyl binding pocket is at capacity. 
The majority of mammalian cell membranes are composed of phosphatidylcholine, with 
phosphatidylethanolamine, sphingomyelin, and cholesterol also abundantly present (Funari et 
al., 2003; van Meer et al., 2008). Unsaturated [oleoyl] C18 or saturated [palmitoyl] C16 are the 
most common lipid chains present in phospholipids. The most efficacious of the lipid inhibitors 
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in this study contain similar tails and therefore may be capable of inserting into the bilayer, 
spanning the depth of one leaflet, and interacting with or displacing membrane lipids at the 
protein membrane interface. The predilection for certain tail lengths and configurations could 
also reflect the capacity for acyl-glycine compounds to associate with the membrane and form 
a lipid-bound pool.  
The arachidonyl tail has multiple double bonds which allow it to exist in a numer of different 
conformations: U-shaped, J-shaped, or in an extended conformation (Figure 3.6A) 
(Makriyannis, 1995). Despite the U-shape conformation possessing the lowest energy, it has 
been shown using solid-state NMR that anandamide exists in an extended conformation within 
the membrane bilayer, with the head group at the phospholipid-aqueous interface and the 
terminal carbon approximately half way across the membrane (Tian et al., 2005). This 
conformation is most similar to monounsaturated lipids, where the cis configuration single 
double bond would create a small kink (Figure 3.6B) and disrupt neighbouring chains. Trans 
double bond containing acyl-glycine compounds would instead behave as unsaturated, 
straight, lipid tails (Figure 3.6C) which can regularly pack within membranes and restrict 
membrane fluidity (Stubbs & Smith, 1984). The inactivity of C18 trans-ω9 Gly may therefore 
reflect movement within the membrane to associate with GlyT2 and cause inhibition. 
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Figure 3.6. Possible conformations of acyl tails. A. N-arachidonyl glycine, B. N-oleoyl 
glycine, and C. C18 trans-ω9 Gly. 
 
Studies of the structure−activity relationship for lipid ligands of CB receptors have also 
revealed that small changes can impart inactivity (Berglund et al., 1998; Lin et al., 1998; Pei 
et al., 2008; Thomas et al., 1996). NAGly and anandamide differ only by a carboxylic acid in 
the head group and yet this difference is sufficient to prevent binding of NAGly. The acyl-
glycine analogues in this study have a preferred double bond position and chain length which, 
in addition to the well characterized importance of the head group, establishes the coinciding 
influence of the tail in conferring the activity of lipid ligands. 
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3.2.6 Reversibility of acyl-glycine inhibitors 
Following a 5 minute washout of each of the active inhibitors, glycine transport currents were 
comparable to pre-exposure transport currents (Figure 3.2). Despite the differences in lipid 
tail, and large variation in relative potency (0.32−9.2 μM), all inhibitors in this study were 
reversible. These observations are in contrast to OLCarn inhibition of GlyT2 which is very 
slowly reversible (Carland et al., 2013). This data suggests that the head group is more 
important in determining the rate of reversibility. The IC50 of OLCarn is similar to the most 
potent acyl-glycine inhibitor (∼320 nM) and so reversibility must be governed by a mechanism 
other than simple unbinding. In the case of OLCarn, application of β-cyclodextrin accelerates 
washout which suggests that it is a lipid membrane-mediated mechanism of inhibition (Carland 
et al., 2013). Thus, I speculate that the head group influences the stability of the lipid in the 
membrane, which can influence the time course of washout of the lipid. Since neither potency 
at the binding site nor hydrophobic interactions of the tail in the membrane are driving 
reversibility, I propose that reversibility is related to how compounds can access or leave the 
site and therefore is another independent property of the compound that must be considered 
when designing an optimal GlyT2 lipid inhibitor. A carnitine head group has a positive charge 
and is significantly larger than the glycine head group, so perhaps the charge and/or size is 
capturing the compounds in a membrane reservoir, such as the negatively charged phosphate 
groups of the lipid bilayer, for longer periods impeding washout. In addition to full inhibition, 
reversibility is another potential problem which is hindering the pursuit of GlyT2 as a molecular 
target. The excitotoxicity of ORG-25543 is associated with both its full and irreversible 
inhibition (Mingorance-Le Meur et al., 2013), and it has been suggested that instead a 
reversible inhibitor may be used to avoid adverse side effects. All inhibitors identified in this 
study are readily reversible within 5 minutes, and may provide insight into the future design of 
reversible inhibitors to circumvent side effects. 
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3.3 Conclusions  
Crystal structures of neurotransmitter transporters with the conserved LeuT-like fold show 
membrane lipids binding to proteins, and these interactions have been proposed to play 
important regulatory roles in their function (Koshy et al., 2013; Penmatsa et al., 2013). I have 
demonstrated that the lipid constituent of acyl-glycine compounds is essential in their specific 
interactions and mechanism of inhibition of the LeuT-like transporter, GlyT2, and not merely a 
nonselective, “sticky” adjunct. The data presented here establishes there is an ideal chain 
length and double bond conformation, and that potency and maximal level of inhibition are 
influenced by the lipid tail. Conservative differences between compounds are sufficient to 
impart or remove inhibitory activity which validates highly specific binding to a subtype 
selective allosteric pocket. 
In this chapter, a number of synthesised acyl-glycine compounds have been shown to inhibit 
GlyT2 over the closely related GlyT1. These compounds contain novel synthetic tails which 
may be less susceptible to enzymatic degradation than the parent compound NAGly. I have 
identified C18 ω8 Gly, a relatively potent (320 nM), reversible, and partial (61 ± 1.7%) novel 
inhibitor of GlyT2 which has low activity on GlyT1 and is ∼28-fold more potent than the 
endogenously produced ligand, NAGly. In addition to improving the potency of GlyT2 
inhibitors, there is a great need to develop effective inhibitors which are partial and reversible 
as to not disrupt the equilibrium cytosolic glycine concentrations, which has to date hampered 
the progress of GlyT2 inhibitors as therapeutics. In this chapter I have identified important 
structural elements which contribute to the overall activity as well as what governs the maximal 
level of inhibition and reversibility characteristics of lipid glycine transporter inhibitors. 
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Chapter 4: N-acyl amino acid inhibitors of GlyT2 for the treatment of neuropathic 
pain 
4.1 Introduction 
Disease or injury to the somatosensory nervous system can cause long-term neuropathic pain, 
characterised by associated hyperalgesia (amplified pain sensation) and allodynia (pain 
response to innocuous stimuli), which produce distinctive symptoms of numbness, burning, 
shooting, and electric-like pain in sufferers (Constigan et al., 2009). A large number of cases 
are refractory to conventional analgesics, perhaps due to adaptations within the CNS 
(Latremoliere & Woolf, 2009). There is therefore a great need to develop new drugs with novel 
targets to treat neuropathic pain. 
A number of GlyT2 inhibitors have been developed which have been shown to be analgesic 
in a number of models of neuropathic pain (Haranishi et al., 2010; Mingorance-Le Meur et al., 
2013; Morita et al., 2008; Omori et al., 2015; Xu et al., 2005), however, many cause significant 
excitotoxic symptoms (Hermanns et al., 2008; Mingorance-Le Meur et al., 2013). Endogenous 
lipid compounds have also been identified as novel agents capable of inhibiting glycine 
transporters. NAGly is a partial, reversible, non-competitive inhibitor of GlyT2 (IC50 ~9 µM) 
with little activity at GlyT1 (Wiles et al., 2006). Other endogenous acyl compounds also inhibit 
the GlyT2 transporter; with an order of potency of OLCarn (340 nM) > NOGly (500 nM) > 
palmitoyl L-carnitine (600 nM) > NAGly > N-arachidonyl alanine (9 µM) > N-arachidonyl GABA 
(12 µM) (Carland et al., 2013; Wiles et al., 2006). These lipid inhibitors of GlyT2 are 
amphipathic; comprised of a long flexible lipid tail conjugated to a charged or polar head group.  
Previous attempts to improve potency and stability led to the synthesis of a series of acyl-
glycine analogues, presented in Chapter 3. It was shown that the lipid tail constituent was 
critical in their activity as inhibitors of GlyT2, and that there was an ideal chain length and 
double bond conformation. C16 cis-ω3 Gly was shown to be a relatively potent (IC50 810 nM), 
partial inhibitor (65% maximal inhibition), while shifting the double bond to the ω7 position 
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produced an inhibitor with a larger maximal level of inhibition (93% maximal inhibition). I 
propose that a reversible, partial GlyT2 inhibitor will allow for sufficient glycine re-uptake into 
presynaptic terminals for loading of vesicles, but will slow the removal of glycine to increase 
transient concentrations at inhibitory glycinergic synapses while minimising spill-over into 
excitatory glutamatergic synapses. 
Lipid GlyT2 inhibitors resemble bioactive lipid molecules, which are long chain fatty chains 
often conjugated to amino acids or neurotransmitters, including acyl-serines, acyl-taurines, 
and acyl-dopamines. These compounds activate specific signalling pathways, and have to 
date been identified within the CNS, immune system, and cardiovascular system (Evans & 
Hutchinson, 2010). The availability of the precursor fatty acids and amino acids suggest that 
there may be other lipids whose role are yet to be determined. In 2010, Tan and colleagues 
identified 50 novel acyl-amino acids present in the rat brain or bovine spinal cord (Tan et al., 
2010). It is proposed there are a number of unknown targets for bioactive lipids, and that acyl-
amino acids are ubiquitous within the CNS. Lipid based drugs may therefore be stable and 
tolerated, however off target side effects will need to be investigated as they have the potential 
to activate other receptors and signalling pathways. 
In Chapter 3, I demonstrated that the lipid tail constituent is critical in the activity of lipid 
inhibitors at GlyT2, and that the most potent chain is 18 carbons in length with a cis-double 
bond in the ω8, ω9, or ω10 positions. To further investigate the structure activity relationship 
of lipid inhibitors, an additional series of lipid analogues were synthesised by Dr Tristan 
Rawling (UTS), in which the optimal oleic [C18 cis-ω9] tail was conjugated to a number of 
amino acid head groups. A range of aliphatic, aromatic, polar, negatively charged, and 
positively charged acyl-amino acids were prepared. The configuration of the amino acids was 
also explored through L- and D- isomers. In this chapter, I report the inhibitory activity of N-
acyl amino acids at GlyT1 and GlyT2. Select compounds were also screened for metabolic 
stability, with the most potent, stable compound, oleoyl [C18 cis-ω9] D-Lys tested for BBB 
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permeability, and ability to reduce allodynia nerve ligation rat model of neuropathic pain, which 
was conducted by Dr Sarasa Mohammadi (USYD). 
4.2 Results and Discussion 
4.2.1 Activity of N-acyl amino acid analogues on GlyT2 and GlyT1 
As previously reported, inward currents were produced following the application of the EC50 
concentration of glycine to oocytes expressing GlyT1 or GlyT2. For GlyT2, these currents were 
reduced or abolished in the presence of acyl-amino acids, while none of the compounds 
displayed considerable inhibition at GlyT1 at concentrations up to 3-10 µM (example traces 
Figure 4.1; Table 4.1). While glycine activated currents are relatively rapid following its 
administration, N-acyl amino acids slowly reduce currents, suggesting the binding site is not 
immediately accessible. Subsequent re-application of glycine 5 minutes following washout of 
the inhibitor results in reduced currents compared to pre-exposure levels, indicative of 
irreversible or slowly reversible inhibition. Concentration-inhibition curves were thus generated 
by applying increasing concentrations of N-acyl amino acid, producing a cumulative inhibition 
response (representative trace shown, Figure 4.1C), with % max inhibition and apparent IC50 
values at GlyT1 and GlyT2 shown in Table 4.1. 
Prolonged application of >10 µM N-acyl amino acids to either transporter expressing, or 
uninjected oocytes, did not produce any currents, with the exception of acyl-serine and 
positively charged N-acyl amino acid compounds. Concentration response curves for these 
inhibitors were therefore limited to 3 µM to circumvent non-specific membrane effects. 
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Figure 4.1. Representative current traces from oocytes expressing glycine 
transporters, clamped at -60 mV. A. the EC50 concentration of glycine (30 µM) was applied 
(open bar) to produce inward currents, which was reduced by application of oleoyl L-Lys (47) 
(grey bar). B. GlyT1 mediated glycine currents were not reduced by (47), even at high 
concentrations. C. Cumulative concentration response curves were generated by applying 
increasing concentrations of acyl inhibitor (28 in this example, grey segmented bar) to reduce 
glycine induced currents at GlyT2.  
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4.2.2 Activity of N-acyl L-amino acids 
Conjugation of the oleoyl tail to an amino acid head group in the L- configuration produced 
compounds which all reduced GlyT2 transport currents, with IC50 values ranging from 25.5 nM 
– 4.35 µM (Table 4.1). For compounds containing small aliphatic side chains (L-Ala (21) and 
L-Val (23)) weaker inhibition was observed (IC50 values > 1 µM) (Figure 4.2A) compared to 
compounds with a larger, bulkier side chain (e.g. L-Leu (25) IC50 143 nM) (Figure 4.2B).  
While methionine is often grouped with aliphatic amino acids, the L-Met analogue (27) is a 
potent, near full inhibitor (29.2 nM, 91.2%) which suggests it may have more than just 
hydrophobic interactions at the binding site. In order to further understand these interactions, 
an N-acyl amino acid was synthesised containing the head group L-NorLeu (29), a straight 
chained isomer of leucine containing a carbon atom in place of the sulfur in methionine. This 
compounds was ~9-fold less potent, indicating the sulfur atom in the L-Met analogue is 
providing additional interactions with GlyT2. This sulfur may also behave as an electrophile; 
the σ-hole of the S possibly interacting with an oxygen atom, or with aromatic π electrons in 
the binding site (Beno et al., 2015; Pal & Chakrabarti, 2001). 
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Figure 4.2. Aliphatic acyl amino acids inhibit glycine transport currents of GlyT2 
transporters expressed in Xenopus laevis oocytes. 30 μM glycine transport currents were 
measured in the presence of lipids in the range of 1 nM to 10 μM. A. Concentration–inhibition 
curves for compounds (21-24). B. Concentration–inhibition curves for compounds (25-29). 
The responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares 
analysis.. 
 
For acidic amino acids where their side chains would be negatively-charged at both assay 
conditions and physiological pH, conjugation to the oleic tail produces active inhibitors of 
GlyT2 (Figure 4.3B). However, these compounds possess relatively low affinity (L-Asp (32) 
865 nM; and L-Glu (34) 4.35 µM), and do not appear to provide any additional activity 
compared to an aliphatic side chain. The L-Asn (36) analogue is similar to L-Asp but instead 
contains a primary amide side chain which is uncharged. The IC50 is largely unchanged (613 
nM) compared to L-Asp which suggests the negative charge is not providing any significant 
binding or repulsive interactions with GlyT2. 
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Figure 4.3. Polar and negatively charged acyl amino acids inhibit glycine transport 
currents of GlyT2 transporters expressed in Xenopus laevis oocytes. 30 μM glycine 
transport currents were measured in the presence of lipids in the range of 1 nM to 10 μM. 
Concentration–inhibition curves for A. Compounds (30) and (31). B. Compounds 32-36. The 
responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis.
 
 
The N-acyl L-amino acids with aromatic side chains are all relatively potent inhibitors of GlyT2 
(Figure 4.4A). The L-Phe analogue (37) inhibited GlyT2 with an IC50 of 214 nM, and extension 
of the alkyl chain between the aromatic ring and amino acid back bone further improved 
potency (L-C2-Phe (39) IC50 151 nM).  The benzene ring of the indole group in L-Trp (41) is 
also 3 bonds from the head group α-carbon and conferred a high potency (IC50 54.6 nM), 
which suggests there is an optimum distance from the amino acid backbone to the aromatic 
group. 
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Figure 4.4. Aromatic acyl amino acids inhibit glycine transport currents of 
GlyT2transporters expressed in Xenopus laevis oocytes. 30 μM glycine transport currents 
were measured in the presence of lipids in the range of 1 nM to 10 μM. Concentration–
inhibition curves for A. Compounds (37, 39, and 41) and B. Compounds (38, 40, and 40). The 
responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis.
 
 
Conjugation of a positively charged L-amino acid to the oleic tail produced analogues which 
were the most potent inhibitors in the N-acyl amino acid series (L-His (43) 130 nM; L-Arg (45) 
47.9 nM; L-Lys (47) 25.5 nM) (Figure 4.5A). Because the L-Lys head group produced the most 
potent inhibitor, 3 compounds were prepared with “lysine-like” side chains, with 1, 2, or 3 
carbons linking the NH3+ to the amino acid backbone (23-25). Shortening the length of this 
linker reduced activity in the order of C4 (L-Lys) = C3 > C2 > C1 (Figure 4.5C). The importance 
of the backbone carboxylic acid was also examined through lysine derivatives; C5-NH3+ (52) 
where the carboxylic acid is removed; and L-Lys-OMe (53) which instead contains a methyl 
ester. In both cases, the compounds were less active than L-Lys (IC50 560 nM and 91.3 nM 
respectively), with complete removal of the carboxylic acid reducing potency by ~22-fold. 
The importance of the tail group was similarly explored with 4 additional compounds 
synthesised with either L- or D- Lys conjugated to a C16- or C18- monounsaturated tail (54-
57). All compounds were active GlyT2 inhibitors (Figure 4.5D) with C16 ω3 L-Lys (56) the most 
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potent (10.7 nM). Interestingly, altering the tail group in this case did not follow the same trend 
as in Chapter 3, where conjugation to the C18 ω5 tail or C16 ω3 tail produced inactive or 
partial inhibitors respectively. 
 
Figure 4.5. Positively charged acyl amino acids inhibit glycine transport currents of 
GlyT2 transporters expressed in Xenopus laevis oocytes. 30 μM glycine transport 
currents were measured in the presence of lipids in the range of 100 pM to 3 μM. 
Concentration-inhibition curves for A. Compounds (43, 45, 47, 53, and 53), B.  Compounds 
(44, 46, and 48), C. Compounds (49-51). Only 1 data point is presented for (31) at the maximal 
concentration (3 μM) as the data could not be reliably fit. D. L- or D- Lys analogues (54-57) 
with differing acyl tails. The responses are normalized mean values ± SEM (n ≥ 3 cells) fit 
using least-squares analysis. 
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4.2.3 Activity of N-acyl D-amino acids 
Comparison of D- and L- enantiomers revealed, with the exception of serine analogues (30 
and 31), the L-enantiomers had equal or greater potency as GlyT2 inhibitors. For compounds 
with a small or flexible side chain, IC50 values for N-acyl D-amino acids were only 2-9-fold 
lower than the corresponding L- isomer. For example, D-Lys (48) is only marginally less potent 
than L-Lys (48.3 nM compared with 25.5 nM). Conversely, N-acyl D-amino acids with a large 
aliphatic or aromatic side chain had significantly reduced activity, particularly for D-C2-Phe 
(40) and D-Trp (42) analogues where negligible inhibition was reached even at maximal 
concentrations (10 µM) (Figure 4.4B), while L- isomers are potent nanomolar inhibitors. 
4.2.4 Structure activity of acyl inhibitors on GlyT2 
The chemical nature of the binding site can also be inferred through structure activity data. A 
methionine-π interaction produces ~4 – 6 kJ/mol (Valley et al., 2012) while a cation-π 
interaction has a value of ~4 kJ/mol; contacts with aromatic residues at the binding site may 
therefore explain the similar affinities between a lysine and methionine containing acyl 
inhibitors. I propose that the head group binding site is likely to be comprised of aromatic 
residues which would provide π-electrons for cation-π (positive amino acids), methionine-π 
(methionine), and π-π (aromatic amino acids) interactions for the most potent acyl inhibitors. 
The side chain binding region is likely to be distant from the backbone carboxylate binding site 
as longer side chains promote greater activity, and orientated in a direction preferred by the 
L-enantiomers. Given the wide range of head groups that are allowed, the binding site must 
also be large and/or flexible to accommodate a number of different chemical groups and 
conformations.  
For the G- protein-coupled receptor family, lysophosphatidic acid (LPA) and sphingosine-1-
phospate lipid ligands contain larger head groups than the endocannabinoids, and yet are 
proposed to fit into a similar pocket. The LPA receptor ligand pocket has head group specificity 
but promiscuous acyl tail binding (Chrencik et al., 2015). This is proposed to be due to two 
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tryptophan residues which in the presence of a lipid, change rotameric states to accommodate 
the ligand and stack their π-electrons towards the tail (Chrencik et al., 2015). Despite the 
GlyT2 substrate site having strict requirements for binding, the allosteric lipid inhibitor binding 
site may lie at a region of the transporter with high flexibility which would allow N-acyl amino 
acids to wiggle into their final binding site, and interact through a number of conformations and 
binding modes.  
The apparent affinity of compounds may also be a reflection of how well N-acyl amino acids 
are able to interact with membranes. The most potent inhibitors have head groups known to 
intercalate with membrane phospholipids. Lysine residues can snorkel below the 
aqueous:bilayer interface to bury it’s aliphatic region within the oily core of the lipid bilayer, 
while the charged amino group can interact at the polar phospholipid head groups. Similarly, 
tryptophan residues prefer to orient themselves towards the polar head group:acyl tail 
interface of membranes (Yau et al., 1998). Most known lipid ligands of membrane proteins 
must interact with the cell membrane to reach their protein binding site. An acyl-amino acid 
which can navigate the membrane more easily may therefore possess a higher apparent 
affinity. 
4.2.5 Maximal level of inhibition 
Positively charged N-acyl amino acids all inhibited glycine transport in the range 71 – 93% 
(Table 4.1). Similarly, all negatively charged N-acyl amino acids produced a high % max 
inhibition (77 – 100%). For aliphatic and aromatic acyl-amino acids, however, the level of 
inhibition was influenced by the size and configuration of the side chain. For these compounds, 
the L- isomer possessed a higher % max inhibition compared to the D- for all cases (for 
example (L-Val) and (D-Val) inhibited 90.1 ± 5.9 and 56.7 ± 5.1, respectively). This was 
particularly apparent for aromatic N-acyl amino acids, where all of the D- compounds displayed 
low level or no inhibition at GlyT2.  
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N-acyl amino acids are large and flexible and could bind in somewhat different overlapping 
conformations in the same binding site. These differences in binding may account for the 
variance in level of inhibition observed for each compound and may be a reflection of the 
stability of inhibitor-bound GlyT2, with some glycine transport still permitted in certain 
conformations. 
It is known that full (100%), irreversible inhibition of GlyT2 produces severe neuromotor and 
respiratory side effects in animal models (Mingorance-Le Meur et al., 2013). While a partial 
inhibitor would preserve vesicle refilling and recycling of glycine, it is unclear how much 
transport should remain for a balance between recycling and efficacious GlyT2 inhibition. 
siRNA targeting the GlyT2 gene reduces protein expression to 30% WT levels with no 
observable adverse effects (Morita et al., 2008); significant reduction (70%) of GlyT2 activity 
should therefore be both safe and efficacious in treating pain. To determine optimal levels of 
inhibition, acyl inhibitors can be tested at ex vivo or in vivo inhibitory glycinergic synapses 
where glycine receptors and transporters are both present.  
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Table 4.1. Structure-activity relationships of amino acid conjugated lipid 
compounds at GlyT2 and GlyT1* 
R
O  
Compound 
Head 
group 
R 
GlyT2 
IC50 (nM) 
GlyT1 
IC50 (µM) 
GlyT2  
% max 
inhibition 
21 L-Ala 
HO2C
NH
 
1230 
(649 – 2340) 
>30a 89.8 ± 5.8 
22 D-Ala 
HO2C
NH
 
2330 
(1.26 – 4.34) 
>30 81.7 ± 6.2 
23 L-Val 
HO2C
NH
 
1170 
(643 – 2120) 
>30 90.1 ± 5.9 
24 D-Val 
HO2C
NH
 
1000 
(448 – 2570) 
>30 56.7 ± 5.1 
25 L-Leu 
HO2C
NH
 
143 
(70.7 – 287) 
>10 72.2 ± 3.8 
26 D-Leu 
HO2C
NH
 
>30 µMa >30 35.6 ± 2.6 
27 L-Met 
HO2C
NH
S
 
29.2 
(18.6 – 45.7) 
>3 91.2 ± 2.7 
28 D-Met 
HO2C
NH
S
 
259 
(79.6 – 845) 
>3 68.6 ± 8.1 
29 L-NorLeu 
HO2C
NH
 
259 
(166 – 372) 
>10 64.5 ± 6.9 
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30 L-Ser 
HO2C
NH
OH
 
496 
(308 – 799) 
>3 73.1 ± 5.1 
31 D-Ser 
HO2C
NH
OH
 
64.8 
(31.1 – 135) 
>3 73.6 ± 4.4 
32 L-Asp 
HO2C
NH
OH
O
 
865 
(468 – 1600) 
>10 76.7 ± 5.3 
33 D-Asp 
HO2C
NH
OH
O
 
1810 
(1050 – 3140) 
>10 92.5 ± 6.9 
34 L-Glu 
HO2C
NH
OH
O
 
4350 
(2350 – 8070) 
>10 100 ± 14.0 
35 D-Glu 
HO2C
NH
OH
O
 
3750 
(2240 – 6260) 
>10 91.6 ± 7.9 
36 L-Asn 
HO2C
NH
NH2
O
 
613 
(265 – 1420) 
>10 92.7 ± 7.2 
37 L-Phe 
HO2C
NH
 
214 
(86.4 – 530) 
>10 54.7 ± 3.8 
38 D-Phe 
HO2C
NH
 
>10 µMa >10 42.3 ± 2.8 
39 
L-C2-
Phe 
HO2C
NH
 
151 
(88.8 – 257) 
>10 75.1 ± 2.9 
40 
D-C2-
Phe 
HO2C
NH
 
>10 µMa >10 10.2 ± 1.2 
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41 L-Trp 
HO2C
NH N
H  
54.6 
(31.4 – 95.8) 
>10 86.2 ± 3.8 
42 D-Trp 
HO2C
NH N
H  
>10 µMa >10 14.2 ± 3.5 
43 L-His 
HO2C
NH
N
H
N
H
+
 
130 
(84.4 - 199) 
>3 78.4 ± 3.4 
44 D-His 
HO2C
NH
N
H
N
H
+
 
313 
(229 – 889) 
>3 82.1 ± 3.3 
45 L-Arg HO2C
NH
NH NH2
+
NH2
 
47.9 
(27.2 – 84.2) 
>3 87.2 ± 3.7 
46 D-Arg HO2C
NH
NH NH2
+
NH2
 
69.2 
(48.0 – 99.9) 
>3 70.9 ± 2.2 
47 L-Lys 
HO2C
NH
NH3
+
 
25.5 
(17.2 – 37.7) 
>3 86.8 ± 2.4 
48 D-Lys 
HO2C
NH
NH3
+
 
48.3 
(37.2 – 62.7) 
>3 91.0 ± 1.9 
49 L-C3-Lys 
HO2C
NH
NH3
+
 
31.6 
(23.1 – 43.3) 
>3 86.0 ± 2.2 
50 L-C2-Lys 
HO2C
NH
NH3
+
 
152 
(100 - 231) 
>3 82.7 ± 3.3 
51 L-C1-Lys 
HO2C
NH
NH3
+
 
182b 
(27.3 – 1210) 
>3 58.2 ± 7.6 
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52 C5-NH3 
NH
NH3
+
 
560 
(312 – 1010) 
>3 86.7 ± 7.2 
53 
L-Lys-
OMe 
MeO2C
NH
NH3
+
 
91.3 
(37.5 - 222) 
>3 78.8 ± 5.8 
Compound 
Tail 
group 
R  
L-Lys or D-Lys 
GlyT2 
IC50 (nM) 
GlyT1 
IC50 (µM) 
GlyT2  
% max 
inhibition 
54 C18 ω5  
HO2C
NH
NH3
+
 
67.5 
(32.6 - 140) 
>3 µM 81.3 ± 5.1 
55 C16 ω7  
HO2C
NH
NH3
+
 
66.6 
(51.1 – 86.8) 
>3 µM 90.2 ± 2.1 
56 C16 ω3  
HO2C
NH
NH3
+
 
10.7 
(8.32 – 13.9) 
>3 µM 94.9 ± 1.6 
57 C16 ω3  
HO2C
NH
NH3
+
 
699 
(367 – 1330) 
>3 µM 91.8 ± 8.2 
*Compounds were tested for inhibition of 30 µM glycine transport by GlyT2 and GlyT1, 
expressed in oocytes. n ≥ 3 with measurements taken from at least 2 batches of oocytes. 
Data presented are mean and 95% confidence intervals or mean ± SEM.   
a. Where significant inhibition was not reached, IC50 are presented as greater than the 
maximum concentration of each compound applied. 
b. Curve could not reliably be fit from the data 
 
4.2.6 Oleoyl L-Lys reduces radiolabelled uptake of GlyT2 expressing oocytes in 
a dose dependent manner 
Lipids are able to exert their effects on membrane proteins through either specific interactions 
with select amino acid residues, or non-specific mechanisms, such as influencing the cell 
membrane. In order to demonstrate that a reduction in glycine-induced currents is directly 
related to the reduced transport by GlyT2 and not GlyT1, [3H]-glycine uptake was performed 
on oocytes expressing either transporter in the presence and absence of oleoyl L-Lys. There 
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was a dose-dependent reduction of [3H]-glycine uptake by GlyT2, and no change of glycine 
uptake by GlyT1, even at high concentrations of oleoyl L-Lys (Figure 4.6). This confirms N-
acyl amino acid compounds are acting through inhibition of GlyT2 mediated glycine transport.  
 
Figure 4.6. Radiolabelled uptake of [3H]-Glycine by GlyT2 but not GlyT1 is inhibited by 
oleoyl L-Lys. Oocytes expressing either transporter or uninjected control oocytes were pre-
incubated for 2 minutes with either 100 nM or 1 µM oleoyl L-Lys (47), followed by measurement 
of 10 µM [3H]-Glycine uptake as described in methods.  
 
4.2.7 Reversibility of N-acyl amino acid inhibitors 
The reversibility of N-acyl amino acid inhibition was investigated by first applying an IC50 
concentration of inhibitor and once a stable level of inhibition was observed, washing the 
recording chamber with buffer. 30 µM glycine was then reapplied at 5 minute intervals 
throughout the wash time course to determine transport recovery, which is indicative of the 
reversibility of an inhibitor (Figure 4.7). For some cells, baselines were observed to drift over 
the course of the assay (Figure 4.8), which is a phenomenon observed both in the presence 
and absence of inhibitor dependent on the health and longevity of the cell. Current values 
were thus adjusted for the shifting baseline. 
At 5 minutes post-inhibition by oleoyl L-Val and oleoyl L-Asp glycine currents were  
77.7 ± 2.6% and 92.4 ± 3.2% respectively, signifying relatively fast reversibility (Figure 4.8A, 
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B).  For L- and D- Lys analogues, recovery was slower, but steady, with most transport restored 
by 30 minutes (Figure 4.8D, E). Transport currents following oleoyl L-Trp application, however, 
did not recover at all throughout the time of the assay (Figure 4.8C), with currents at 30 
minutes no greater than time 0 (43.0 ± 3.1% and 36.7 ± 5.1% respectively). As each inhibitor 
was assayed at its own IC50, washout rates of compounds with similar potencies should have 
been comparable if it was a simple binding and unbinding reaction. Instead, reversibility was 
shown to be dependent on the head group, but this effect was not directly correlated with 
potency. Oleoyl L-Trp (IC50 54.6 nM) showed no recovery whilst oleoyl L-Lys (IC50 25.5 nM) 
displayed considerable recovery after 30 minutes. The time taken to reach a stable level of 
inhibition also differed for each N-acyl amino acid. While application of glycine results in rapid 
inward currents, inhibition of this current by lipid inhibitors is comparably slow. Inhibition by L-
Val and L-Asp analogues was faster than L-Lys and D-Lys, and L-Trp took ~10 minutes to 
reach a plateau of inhibition (Figure 4.8). Lipid ligands of membrane proteins are often 
proposed to first diffuse into the membrane before activating or inhibiting their targets. The 
slow rate of onset may therefore be a reflection of membrane insertion. 
 
Figure 4.7. Reversibility time course for N-acyl amino inhibition of GlyT2. The EC50 
concentration of glycine was applied to GlyT2 expressing oocytes to determine the maximal 
current at this dose. Acyl inhibitors were then co-applied with glycine at time 0, and then 
washed from the recording chamber. EC50 glycine was then reapplied at 5 minute intervals 
over a 30 minute period. Transport recovery for each compound is presented as I/Imax. 
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Figure 4.8. Representative traces for reversibility of select N-acyl amino acids. Glycine 
EC50 (open bars) was applied to GlyT2 expressing oocytes until stable transport was reached. 
The IC50 concentration of N-acyl amino acids was then co-applied (grey bars) until inhibition 
reached a plateau. Buffer was subsequently perfused over the oocytes for 30 minutes with the 
EC50 concentration of glycine reapplied at 5 minute intervals to check the transport recovery. 
A. oleoyl L-Val B. oleoyl L-Asp C. oleoyl L-Trp D. oleoyl L-Lys E. oleoyl D-Lys. Dashed lines 
are indicated for Imax and level of inhibition. 
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The GlyT2 lipid inhibitor OLCarn shows partial recovery after 30 minute washout, but the level 
and rate of recovery can be enhanced with the lipid extruding compound β-cyclodextrin 
(Carland et al., 2013). A tryptophan head group may increase the affinity for cell membranes 
by burying at the phospholipid head group:acyl tail interface (Yau et al., 1998). This membrane 
affinity may contribute to the irreversibility of oleoyl L-Trp and slow reversibility of other acyl 
amino acids. 
The apparent irreversibility of the L-Trp analogue could also simply be a reflection on the large 
size of the head group. Perhaps once the compound is lodged within its GlyT2 binding site 
there is much less protein flexibility and freedom for the N-acyl amino acid to be removed. The 
other amino acid head groups are considerably more flexible, which may explain their 
reversibility. 
4.2.8 Metabolism of oleoyl L-Lys and oleoyl D-Lys 
N-acyl amino acids may be metabolised through several pathways that can limit their in vivo 
half-lives and therapeutic potential. The amide bonds in N-acyl amino acids are likely to be 
cleaved by hydrolytic enzymes, such as fatty acid amide hydrolase (FAAH) (Giang & Cravatt, 
1997), and may also be susceptible to oxidative metabolism, including cytochrome P450 
hydrolates (Bornheim et al., 1995) and lipoxygenases (Ueda et al., 1995). Thus, the stability 
of L-Lys and its D-enantiomer towards hydrolysis in plasma and cytochrome P450-mediated 
oxidation in liver microsomes were assessed (Table 4.2). Stability assays were performed by 
the Centre for Drug Candidate Optimisation (CDCO) at Monash University. 
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Table 4.2. Degradation half-lives of N-acyl amino acids in rat plasma and liver 
microsomes 
Head group 
Degradation half-life (t1/2; min) 
Plasma Liver microsomes 
L-Lys 86 54 
D-Lys > 1022a > 255 a 
 a. Minimal degradation (˂15%) was observed over the course of the plasma (240 minute) or 
liver microsome (60 minute) incubation period. 
 
 
The L-Lys analogue displayed degradation half-lives of 86 minutes and 54 minutes in the rat 
plasma and liver microsome assays respectively. Interestingly D-Lys did not exhibit 
measurable degradation in either assay. It is likely that the unnatural head group orientation 
hinders its ability to fit within the active site of the hydrolytic enzyme/s. It is important to note 
that hydrolysis studies in plasma do not take into account degradation by FAAH, an important 
hydrolytic regulator of anandamide (N-arachidonyl ethanolamide) activity (Giang & Cravatt, 
1997). FAAH is a membrane bound enzyme and as such will not be present in plasma. 
However, the observed stability of D-Lys in vivo demonstrates that incorporation of an 
unnatural head group configuration can improve stability to N-acyl amino acids, and that D-
Lys may be sufficiently stable to achieve therapeutic effect. 
4.2.9 Blood brain barrier permeability of oleoyl D-Lys  
GlyT2 is expressed within the dorsal horn of the spinal cord and for GlyT2 inhibitors to show 
in vivo efficacy they must cross the blood brain barrier. Structurally similar lipids including 
anandamide (Maccarrone et al., 2005) and DHA-dopamine (Shashoua & Hesse, 1996) are 
both able to cross the blood brain barrier and it was anticipated that oleoyl D-Lys would display 
similar permeability. This was tested directly by studying the pharmacokinetics and brain 
penetration in vivo following intraperitoneal bolus injection into rats, with the Cmax, Tmax, 
terminal half-life (t1/2), AUC0-24h, and total brain-to-plasma ratio (B/P) presented in Table 4.3. 
This service was also performed by CDCO. 
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Following administration oleoyl D-Lys was rapidly adsorbed with maximum plasma 
concentrations observed at the first time point (1 hour).  It was then slowly cleared from plasma 
with a terminal half-life (T1/2) of 10 hours. Conversely, oleoyl D-Lys concentrations in the brain 
were steady for the length of the sampling period. The Cmax in the brain was 1854 ng/g 
(approximately 4.5 µM), which is well above the IC50 value at GlyT2 (48.3 nM). The B/P ratio 
increased over the sampling period from 0.08 at 1 hour to 1.1 at 24 hours, and a time averaged 
B/P ratio of 0.31 was calculated from the AUC0-24h values. Collectively, these results show that 
oleoyl D-Lys is stable in vivo and can cross the BBB. 
Table 4.3. Pharmacokinetic parameters of 28 after intraperitoneal administration of a 
single 27.5 mg/kg dose in Sprague Dawley rats.  
Parameter Plasma Brain 
Cmax (ng, mL, ng/g) 16690 1854 
Tmax (h) 1 24 
t1/2 (h) 10 c.n.c. 
AUC0-24 (ng*h/mL, ng*h/g) 122473 38479 
Time averaged B/P ratio 0.31 
Male Sprague Dawley rats received a single intraperitoneal dose of oleoyl D-Lys (27.5 mg/kg) and 
plasma and brain concentrations were measured over a 24-hour period. Concentration max (Cmax), 
time at max concentration (Tmax), half-life (t1/2), and area under the curve (AUC) was calculated from 
the data. 
c.n.c – Could not calculate as the flat profile precluded an estimation of half life 
 
4.2.10 Analgesic activity of oleoyl D-Lys on a partial nerve ligation rat model of 
neuropathic pain 
Encouraged by the stability of oleoyl D-Lys and its ability to cross the BBB, male Sprague 
Dawley rats with a partial nerve ligation injury were tested for allodynia following an 
intraperitoneal injection at varying concentrations of oleoyl D-Lys (Figure 4.9). Healthy rats 
tolerated pressures of 12.3 ± 1.6 g (low dose group) and 14.2 ± 0.84 g (high dose group) Von 
Frey filaments. This tolerance was markedly reduced following partial nerve ligation surgery 
which induces a neuropathic pain phenotype in rats (low dose 0.20 ± 0.0 g; and high dose 
0.93 ± 0.73 g). Intraperitoneal injection of either 3 mg/kg or 30 mg/kg of oleoyl D- Lys; 
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increased the paw withdrawal threshold to a peak pressure of 3.1 ± 1.0 g and 8.5 ± 3.2 g 
respectively, 15 minutes following administration, which were then reduced for the length of 
the testing period. Overall, there was a dose dependent reduction in allodynia experienced by 
partial nerve ligation injured rats following intraperitoneal injection of oleoyl D-Lys; this inhibitor 
is therefore likely to cross the BBB to achieve on target effects at glycinergic inhibitory 
synapses in the dorsal horn of the spinal cord.  
Any treatment for chronic pain will be ongoing, and further studies on the long-term application 
of oleoyl D-Lys should be performed. Oleoyl D-Lys persists in brain tissue and is degraded 
slowly which may allow for accumulation in the CNS. N-acyl amino acids which are not full 
inhibitors will still allow for vesicular recycling of glycine, and in this case long-term stability of 
compounds may prove beneficial for long term efficacy, and may circumvent adverse side 
effects associated with full, irreversible inhibition. 
 
Figure 4.9. Von Frey threshold for partial nerve ligation injured rats following injection 
of oleoyl D-Lys. Male Sprague Dawley rats were tested for allodynia using the Von Frey test. 
Paw withdrawal was measured prior to and following a partial nerve ligation surgery (time 0). 
Following low dose (3 mg/kg) or high dose (30 mg/kg) bolus intraperitoneal injections of oleoyl 
D-Lys, paw withdrawal was again measured over the course of 180 minutes. Data are 
averages ± SEM from n=3. Performed by Dr Sarasa Mohammadi (USYD). 
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4.3 Conclusions 
By conjugating a broad range of amino acids to the [C18 cis-ω9] oleoyl tail, a large pool of 
inhibitors of GlyT2 have been identified, most of which have similar or improved potency 
compared with NAGly and other acyl-glycine compounds. It has been determined that N-acyl 
amino acids are active with the order of potency: positively charged > aromatic >> aliphatic > 
negatively charged, and that L- isomers are more active than D-isomers in majority of cases. 
Although both positive and negative side chains are accommodated, a positively charged side 
chain confers a much higher (~85-fold) apparent affinity, which implies information about 
molecular determinants of the binding site. I propose that the binding site is comprised of 
aromatic amino acids to coordinate the head group, and a structurally defined aliphatic cavity 
to cradle the ideal [oleoyl] acyl tail. 
While oleoyl L-Lys (IC50 25.5 nM), has an apparent affinity ~353-fold higher than NAGly, it is 
limited by its metabolic instability. The D-enantiomer is also a potent GlyT2 inhibitor (IC50 48.3 
nM), is metabolically stable, and is rapidly absorbed into the CNS following IP administration. 
It has also been demonstrated that oleoyl D-Lys is antiallodynic in preliminary pain studies of 
PNL rats. In this chapter I have expanded the pool of GlyT2 lipid inhibitors to include a broad 
range of lipids with different properties. I have revealed important moieties which confer faster 
or slower rates of reversibility, different levels of inhibition (57 – 100%), and identified 12 
inhibitors with an IC50 value below 100 nM. GlyT2 is a challenging drug target as many 
compounds which have been developed to target GlyT2 display undesirable inhibitory 
properties (irreversibility, full inhibition). It is presently unknown which attributes are ideal in 
vivo, and perhaps by testing a range of different inhibitors optimal properties can be resolved. 
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Chapter 5: Molecular determinants for acyl amino acid inhibition of GlyT2 
5.1 Introduction  
Structure-activity studies of acyl inhibitors provide insight into binding, but, it is still unknown 
how they interact with GlyT2 to cause inhibition. At present there are no crystal structures of 
glycine transporters, however crystal structures of related transporters in different 
conformational states can help to infer regions of GlyT2 that may influence lipid interactions 
and be involved in the mechanism of inhibition by acyl amino acids. Crystal structures of the 
dopamine (DAT), serotonin (SERT), and bacterial leucine (LeuT) transporters, suggest a 
common transport mechanism where; substrate and co-transported ions enter the aqueously 
accessible extracellular facing vestibule; large movements of extracellular loop 4 (EL4) close 
the extracellular gate; and rearrangement of core transmembrane (TM) helices allow TM1a to 
swing open and release substrate into the cytoplasm (Coleman et al., 2016; Krishnamurthy & 
Gouaux, 2012; Penmatsa et al., 2013, 2015; Wang et al., 2015; Yamashita et al., 2005). While 
members of this family share a common transport mechanism, they differ in the population of 
co-transported ions, and molecular determinants of the substrate binding sites. GlyT2 
possesses the smallest substrate binding site and only permits the binding of the simplest 
amino acid, glycine. We have shown previously that mutation of the substrate site allows for 
transport of larger amino acids (Carland et al., 2018), but that these mutant transporters are 
not differentially inhibited by NAGly and OLCarn (unpublished data). Additionally, it has been 
demonstrated that NAGly and OLCarn do not competitively inhibit transport of glycine (Carland 
et al., 2013; Wiles et al., 2006).  It appears that lipid inhibitors bind allosterically to GlyT2, but 
this site remains elusive.  
In addition to substrate bound crystal structures of neurotransmitter transporters, there are a 
number of inhibitor bound structures which can give insight into transport-unfavourable 
conformations. In each of the inhibitor bound structures of Drosophila DAT (dDAT) and human 
SERT (hSERT), the transporters are in outward-open conformations with core TM helices in 
- 88 - 
 
positions incongruous with the occlusion of the binding site. In the nortriptyline bound dDAT 
structure (Penmatsa et al., 2013) there is a 10 Å opening compared to the occluded substrate 
bound structure of LeuT (Yamashita et al., 2005), which suggests inhibitors that bind in the 
primary site stop transport by preventing the closure of the extracellular gate. Additionally, 
LeuT has been shown to favour the outward-open conformation in the presence of β-octyl 
glucoside, even when Na+ and leucine are present (Kazmier et al., 2014). It is apparent that 
stabilisation of the outward-open conformation is a common mechanism for inhibitors of the 
NSS transporters which prevent transport even in otherwise transport-favourable conditions. 
In addition to structures of classical NSS inhibitors bound within the central cavity of these 
transporters, a structure of dDAT has been elucidated which has a cholesterol molecule bound 
to a membrane-exposed surface of the transporter, between helices TM1a, TM5, and TM7 
(Penmatsa et al., 2013). It has been suggested that cholesterol may be an allosteric modulator 
of dopamine transport; its presence in this membrane exposed cavity may inhibit important 
conformational changes of TM1a required for transport (Zeppellin et al., 2018). While glycine 
transporters do not appear to be modulated by membrane cholesterol (Liu et al., 2009), this 
site may be conserved within GlyT2, as it is proposed to similarly inhibit serotonin and 
noradrenaline transporters (Zeppellin et al., 2018).  It has also been demonstrated in our lab 
that mutation of the equivalent TM1a residues in GlyT2 does not abolish inhibition by lipid 
inhibitors (unpublished data); however it is possible that there are a number of similar lipid 
binding sites on GlyT2. Rates of OLCarn reversibility are slow, and this can be accelerated 
using the membrane lipid extruding compound, β-cyclodextrin, which suggests lipid inhibitors 
may interact at membrane exposed region of GlyT2 (Carland et al., 2013). 
While intracellular hinging of TM1a is necessary for substrate release into the cytoplasm, large 
extracellular movements of EL4 are required to occlude the substrate and close the 
extracellular gate. Lipid inhibitors could similarly target any region which must undergo 
substantial conformational changes. EL4 is essential for the inhibition of GlyT2 by the inhibitors 
NAGly and OLCarn; chimeric GlyT2 transporters containing an EL4 region from GlyT1 
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(GlyT2(GlyT1-EL4)) are insensitive to inhibition (Carland et al., 2013; Edington et al, 2009). 
Furthermore, a single point mutation in EL4, I545L, results in transporters with reduced 
sensitivity to lipid inhibitors. These compounds may inhibit GlyT2 by obstructing the 
movements of EL4, locking it in a conformation that is not conducive to transport. 
The membrane exposed transmembrane domains TM7 and TM8 flank EL4 (Figure 5.1) and 
guide its movements. For example, TM7 tilts 17º from the core of the transporter to allow EL4 
to plug the vestibule (Kazmier et al., 2014; Krishnamurthy & Gouaux, 2012). TM7 and TM8 
are both membrane exposed helices that could provide a point of interaction between protein 
and membrane for GlyT2 lipid inhibitors, which may greatly influence the movements of EL4 
to stall transport of glycine. In this chapter, I generated 14 mutant glycine transporters with 
changes to EL4, TM7, and TM8, as well as the adjacent helices TM1, TM3, and TM5, to tease 
out the mechanism of inhibition by different acyl-glycine and acyl amino acid inhibitors 
presented in the previous chapters. 
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Figure 5.1. Homology model of GlyT2 shown in plane of the membrane. A. front face and 
B. reverse face. Mutated helices and loops are coloured, EL4 (orange), TM1 (red), TM3 (blue), 
TM5 (yellow), TM7 (purple), and TM8 (teal). 
 
5.2 Results and Discussion 
5.2.1 Oleoyl L-Lys is not a competitive inhibitor of GlyT2 
GlyT2 possesses the smallest substrate binding site of the NSS family and is only able to 
transport the smallest amino acid, glycine (Carland et al., 2018). While NAGly contains a 
glycine head group, it is conjugated to a large polyunsaturated lipid tail via its backbone 
nitrogen. This adds considerable bulk to the compound, and removes the capacity for the 
amine to form important interactions in the glycine binding site. NAGly has also been 
previously shown to be a non-competitive GlyT2 inhibitor (Wiles et al., 2006), and is therefore 
unlikely to bind at a site overlapping the substrate binding site. Similarly, it has been 
demonstrated that OLCarn displays a mixed mechanism of inhibition at GlyT2 (Carland et al., 
2013). 
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The synthesised N-acyl amino acids presented in Chapter 4 contain side-chains that add 
additional bulk to the head group, making them larger and chemically different to the glycine 
head group of NAGly. To ascertain whether these N-acyl amino acids are likely to possess a 
similar mechanism of inhibition, glycine concentration responses were measured in the 
presence of increasing concentrations of oleoyl L-Lys (Figure 5.2A). The apparent affinities for 
glycine at each concentration of inhibitor (EC50 [10 nM inhibitor] = 14.0 ± 2.7 µM; [30 nM 
inhibitor] = 23.5 ± 8.0 µM; [1 µM inhibitor] = 12.8 ± 7.6 µM) were not significantly different to 
the EC50 for glycine transport in the absence of any inhibitor (15.8 ± 1.3 µM). Conversely, the 
Imax was significantly reduced for all concentrations of C18 ω9 L-Lys (% Imax [10 nM] = 82.8 ± 
4.0%*; [30 nM] = 62.4 ± 5.8%***; [1 µM] = 30.2 ± 4.4%***). This indicates that oleoyl L-Lys 
acts as a non-competitive inhibitor of GlyT2, however an Eadie-Hofstee plot of the data 
suggests that the mechanism may not be purely non-competitive (Figure 5.2B).  Lipid inhibitors 
may display a mixed mechanism of action where the allosteric inhibitor site greatly influences 
glycine binding at the substrate site. It has previously been shown that residues at the 
substrate binding site are not important for the mechanism of inhibition (unpublished data). It 
is unlikely that large bulky acyl inhibitors bind in the narrow substrate binding cavity at the 
base of the extracellular vestibule, and rather cause inhibition through action at another 
allosteric site, which is the focus of this thesis chapter. 
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Figure 5.2. Oleoyl L-Lys reduces concentration-dependent glycine currents. A. 
Concentration-dependent glycine transport currents with increasing concentrations of oleoyl 
L-Lys. ANOVA tests were performed for EC50 and Imax values B. Eadie-Hofstee plot of data 
from A. C. Representative linear fit of hypothetical competitive (blue) or non-competitive (red) 
inhibitors using an Eadie-Hofstee transformation. The data in panels A and B do not fit either 
case.  
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5.2.2 Screening of residues which may be involved in the mechanism of 
inhibition by lipid inhibitors 
To locate the allosteric binding site of lipid GlyT2 inhibitors, a selection of mutations were 
made (Figure 5.3, Figure 5.4) which were either in close proximity to EL4 (TM1: 
A221C/F222Y/Q223R; TM3: F302A and S304A; TM5: R439L; TM8: P561S, F562L, and 
W563L; EL4: Y550L and E552A), or in membrane exposed regions which may influence the 
movements of EL4 (TM5: F428A; TM7: C507I and F515Y; TM8: L569F). GlyT1 is 48% 
identical to GlyT2 (Morrow et al., 1998) and yet it is insensitive to acyl inhibition. This 
differential sensitivity was used to identify potential residues for mutation and where aligned 
residues in each of the TM domains differed between GlyT1 and GlyT2, the GlyT2 residue 
was mutated to the corresponding residue in GlyT1. Mutations were also selected using 
structure activity data presented in previous chapters which suggests that aromatic residues 
may play a role in coordinating the head group of acyl amino acids.  
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Figure 5.3. Sequence alignment of GlyT2, GlyT1, DAT, and LeuT. Regions of interest are 
coloured TM1 (red), TM3 (blue), TM5 (yellow), TM7 (purple), EL4 (orange), and TM8 (teal) 
corresponding to Figure 5.1. Conserved residues are coloured grey. I545 is indicated with a 
green box, and residues which were mutated are indicated with cyan boxes. 
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Figure 5.4. Location of mutated residues on GlyT2. A. Reverse face B.  Top down. 
Residues which were mutated are shown in sticks and coloured cyan (carbon), red (oxygen), 
blue (nitrogen). I545 is also shown in green sticks. EL4 is coloured orange. 
 
For WT GlyT2, co-application of 1 µM OLCarn with the EC50 concentration of glycine reduces 
currents by 60.3 ± 2.8% (Figure 5.5); this dose is sufficient to observe any changes in OLCarn 
sensitivity. Therefore, in order to determine differential inhibition by mutant transporters, this 
dose was applied as an initial screen. None of the mutants in TM1 or TM3 displayed any 
change in inhibition compared to WT (Figure 5.5). Similarly, inhibition of R439L, C507I, E552A, 
and F562L transporters were comparable to WT.  
F428A, Y550L, P561S, W563L, and L569F transporters were less sensitive to inhibition by 
OLCarn with inhibition only reaching 14.9 – 29.0%. Conversely, the TM7 mutant F515W 
increased the inhibitory effect, with transport inhibited 93.8 ± 3.7%. For each of the mutants 
with differential sensitivity at the screening dose, concentration response curves for select lipid 
inhibitors were performed. Additionally, I545L (Carland et al., 2013; Edington et al., 2009) was 
re-examined to determine its importance with the new group of synthesised N-acyl amino acid 
inhibitors. 
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Figure 5.5. Inhibition of WT and mutant GlyT2 transporters by 1 µM OLCarn. Glycine was 
applied to transporters followed by co-application of glycine and OLCarn until a plateau in 
inhibition was reached. The reduced glycine transport currents were normalised to the current 
elicited by the initial glycine application. Data represented are means ± SEM (n ≥ 3) with **** 
p <0.001 following a one way ANOVA. 
5.2.3 Glycine affinity of mutant transporters 
The function of mutant transporters was tested to ensure any small changes in the protein did 
not greatly affect glycine transport. Although the mechanism of inhibition does not appear to 
be affected by glycine concentrations, some residues which were mutated are important in the 
mechanism of transport, particularly residues in TM8 which partially form the glycine and one 
of the Na+ binding sites. For GlyT2 and GlyT1 WT transporters, the obtained EC50 values are 
consistent with published values (12 µM and 20 µM respectively; Vandenberg et al., 2007). All 
mutants tested were functional glycine transporters, with small but non-significant deviations 
in EC50 compared to WT GlyT2 or GlyT1 (Figure 5.6, Table 5.1). The EL4 mutations in both 
GlyT2 and GlyT1 (Y550L and L425I respectively) have reduced glycine affinities compared to 
WT. EL4 plays an important role in extracellular gating which may explain these differences. 
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Figure 5.6. Glycine dependent transport currents for WT and mutant transporters. A. 
GlyT2 and B. GlyT1. Transport currents were measured in the presence of increasing 
concentrations of glycine (1 – 300 μM). Currents were fit to the modified Michaelis-Menten 
equation (see methods) and normalised to the calculated Imax. Data shown represents mean 
± SEM (n ≥ 3). 
Table 5.1. EC50 values for glycine transport of WT and mutant GlyT2 and GlyT1 
transporters. 
Region Mutation Glycine EC50 (µM) 
GlyT2 
GlyT2 WT  14.5 ± 2.6 
EL4 Y550L 62.2 ± 11.4 
TM8 P561S 15.5 ± 4.1 
 W563L 4.9 ± 0.8 
 L569F 7.0 ± 0.6 
TM5 F428A 6.2 ± 0.4 
TM7 F515W 7.1 ± 0.7 
GlyT1 
GlyT1 WT  14.4 ± 1.2 
EL4 I425L 45.1 ± 9.6 
Glycine concentration response curves were performed on WT and mutant transporters to 
generate EC50 values. A one-way ANOVA determined any difference in mutant GlyT2 affinity 
compared to WT GlyT2. A two-tailed t test compared mutant (L425I) GlyT1 with WT GlyT1. 
No EC50 values were considered significantly different than WT. 
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5.2.4 Differential selectivity of GlyT1 and GlyT2 
It has been suggested that a single amino acid residue difference at the tip of EL4 (Figure 5.4) 
between GlyT1 and GlyT2 is responsible for the differential selectivity of OLCarn. Substitution 
of I545 with a leucine residue reduces GlyT2 inhibitor sensitivity to that of GlyT1 (Carland et 
al., 2013). To determine whether I545 is as critical to inhibition by the newly synthesised 
compounds in Chapter 4, a selection of N-acyl amino acids were applied to the I545 mutant 
(Figure 5.7). It was shown that acyl compounds with a diverse range of head groups (L-Val, L-
Asp, or L-Trp) have a drastically reduced apparent affinity and maximal level of inhibition 
(Table 5.2). For the L-Lys compound however, while the IC50 is ~17-fold higher, 80.7% 
inhibition could still be attained, which is significantly greater than the activity at WT GlyT1. 
Though clearly important, I545 is not the only molecular determinant for specificity of lipid 
GlyT2 inhibitors. 
 
Figure 5.7. Acyl amino acids inhibit glycine transport currents of I545L mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 23 and 
32. B. Concentration–inhibition curves for compounds 41 and 47. The responses are 
normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis. WT GlyT2 data 
has been shown in the previous chapters but is included for comparison (black curves). I545L 
is shown in teal.  
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While inhibition of the GlyT2(GlyT1-EL4) chimera is comparable to GlyT1, the reverse 
GlyT1(GlyT2-EL4) chimera remains insensitive to NAGly but has increased sensitivity to N-
arachidonyl L-alanine (Edington et al., 2009). To further investigate the selectivity, I created 
the corresponding reverse GlyT1 single point mutation, L425I. For lipid inhibitors with a Gly 
head group, L425I is insensitive, similar to the GlyT1 response; but inhibition of L425I by 
OLCarn is comparable to WT GlyT2 (IC50 195 nM; max. inhibition 74.6%). It is striking that 
such a conservative mutation is sufficient to impart the OLCarn GlyT2 inhibitory phenotype 
into GlyT1. Thus it appears that the binding site must be mostly formed in GlyT1, and the 
selectivity for the compounds may lie in the mechanism of inhibition rather than the binding 
itself.  
 
Figure 5.8. Acyl amino acids inhibit glycine transport currents of L425I mutant GlyT1 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 1 and 
2. B. Concentration–inhibition curves for OLCarn. The responses are normalized mean values 
± SEM (n ≥ 3 cells) fit using least-squares analysis. WT GlyT2 data has been shown in the 
previous chapters but is included for comparison (black curves). GlyT1 L425I is shown in pink.
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5.2.5 Y550 is important in the mechanism of inhibition by lipid GlyT2 inhibitors 
EL4 is important in conferring selectivity for GlyT2 over GlyT1, but little is understood about 
the binding site of lipid inhibitors. Previous investigation of EL4 involved the creation of single 
point mutations of residues that differ between GlyT1 and GlyT2. As I propose the binding site 
is partially formed in GlyT1, residues which are conserved between the two may also be 
important for binding. Y550 (Y430 in GlyT1, Figure 5.3) lies approximately one turn of the helix 
up from I545 and, in our homology model, points into what may be a substantial cavity between 
EL4, TM5, TM7, and TM8 (Figure 5.9).  
Figure 5.9. Location of mutations in EL4. EL4 is shown in orange, TM5 shown in yellow, 
TM7 shown in purple, and TM8 shown in teal. A. In plane of the membrane from the reverse 
face and B.  Top down. Y550 (cyan spheres) is approximately one turn of the helix up from 
I545 (green spheres). 
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All of the acyl amino acids tested had reduced apparent affinity and maximal level of inhibition 
to the Y550L mutant (Table 5.2), which suggests both binding and ability to cause inhibition is 
affected. The effect of compounds with larger L-Trp and L-Arg head groups was most striking, 
with transport in the presence of the acyl amino acid unchanged compared to transport in the 
absence of inhibitor (IC50 >3 µM for Y550L compared to 54.6 nM and 47.9 nM for WT 
respectively) (Figure 5.10C, D), where smaller head groups (Gly) and aliphatic side chains (L-
Leu and L-Val) had IC50 values only 1.5-3-fold higher than WT GlyT2. 
 
Figure 5.10. Acyl amino acids inhibit glycine transport currents of Y550L mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 2 and 
23. B. Concentration–inhibition curves for compounds 30 and 32. C. Concentration–inhibition 
curves for compounds 25 and 41. D. Concentration–inhibition curves for compounds OLCarn, 
45, 47, 48, and 56. The responses are normalized mean values ± SEM (n ≥ 3 cells) fit using 
least-squares analysis. WT GlyT2 data has been shown in the previous chapters but is 
included for comparison (black curves). Y550L is shown in purple.
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5.2.6 Mutations to the top of TM8 disrupt lipid head group interactions 
As EL4 shifts into the vestibule, it packs tightly to core helices, including TM8 to close the 
extracellular gate (Forrest et al., 2008; Krishnamurthy & Gouaux, 2012). I545 and Y550 in EL4 
are oriented towards the top half of TM8, near P561 and W563 (Figure 5.11), which were 
identified to be important in the mechanism of OLCarn inhibition in the initial screen. Inhibition 
of P561S by Gly and L-Val acyl amino acids is comparable to WT GlyT2, whereas lipids with 
larger or more sterically restricted head groups (L-Carn, L-Trp, and D-Lys) have reduced 
apparent affinities (Figure 5.12C, D), similar to the Y550L mutant. P561 is the first residue at 
the top of TM8, where the helix breaks into a small unwound region before EL4 begins. 
Mutation of P561 may therefore alter the connection between TM8 and EL4, extending the 
helix and changing the shape of the gap between the two domains. This could limit the pocket 
size available to acyl amino acid inhibitors with larger head groups. 
 
Figure 5.11. Location of mutations at the top of TM8. EL4 is shown in orange, TM5 in 
yellow, TM7 in purple, and TM8 in teal. A. In plane of the membrane from the reverse face B.  
Top down. Mutated residues are shown in cyan spheres. I545 is in green spheres.  
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Figure 5.12. Acyl amino acids inhibit glycine transport currents of P561S mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 2 and 
23. B. Concentration–inhibition curves for compounds 25 and 41. C. Concentration–inhibition 
curves for compound 41. D. Concentration–inhibition curves for compounds OLCarn, 47 and 
48.  The responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares 
analysis. WT GlyT2 data has been shown in the previous chapters but is included for 
comparison (black curves). P561S is shown in blue.
 
 
Tryptophan residues at the intra- and extra- cellular edges of helices often interact with polar 
head groups of membrane phospholipids (Yau et al., 1998). W563 lies two residues down at 
the top of TM8 (Figure 5.11) and may have a capacity to interact with amphipathic lipid inhibitor 
compounds. Mutation to a leucine (W563L) has no effect on inhibition by the nucleophilic or 
acidic acyl amino acids, L-Ser and L-Asp (Figure 5.13B). Conversely, the activity of L-Trp 
- 104 - 
 
(Figure 5.13C), L-Lys, D-Lys, and L-Carn (Figure 5.13D) lipid inhibitors were all reduced 
compared to WT GlyT2. The difference in selectivity for this tryptophan residue may be due to 
the contribution of π electrons for π-π and cation-π interactions with aromatic or positively 
charged head groups respectively.The differential selectivity of P561S and W563L for acyl 
inhibitors containing different amino acids suggests they may comprise part of the binding site 
that coordinate the head group. 
 
Figure 5.13. Acyl amino acids inhibit glycine transport currents of W563L mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 2 and 
23. B. Concentration–inhibition curves for compounds 25 and 41. C. Concentration–inhibition 
curves for compound 41. D. Concentration–inhibition curves for compounds OLCarn, 47 and 
48.  The responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares 
analysis. WT GlyT2 data has been shown in the previous chapters but is included for 
comparison (black curves). W563L is shown in red.
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5.2.7 Mutations of membrane exposed medial TM5 and TM8 residues disrupt 
lipid tail group interactions 
Because of the relatively slow rate of onset by lipid inhibitors it was postulated that the site 
may be formed or partially formed with membrane exposed regions of GlyT2. L569 (TM8) and 
F428 (TM5) are located approximately medial on each transmembrane helix (Figure 5.14), 
and are likely to be buried in the hydrophobic core of the lipid bilayer. Both the L569F and 
F428A mutant transporters had reduced inhibition by acyl inhibitors containing the C18 ω9 
“oleoyl” tail, but had no effect on NAGly which contains instead a polyunsaturated C20 
“arachidonyl” tail (Figure 5.15, Figure 5.16). This effect was most pronounced for F428A, and 
so this mutant was further explored using a range of acyl-glycine compounds from Chapter 3 
(Figure 5.16). 
Figure 5.14. Location of membrane exposed mutants in TM5 and TM8. EL4 is shown in 
orange, TM5 in yellow, TM7 in purple, and TM8 in teal. A. In plane of the membrane from the 
reverse face B. Top down. Mutants are shown in cyan spheres. I545 is in green spheres. 
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Figure 5.15. Acyl amino acids inhibit glycine transport currents of L569F mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for compounds 1 and 
2. B. Concentration–inhibition curves for compound OLCarn 47. The responses are 
normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis. WT GlyT2 data 
has been shown in the previous chapters but is included for comparison (black curves). L569F 
is shown in yellow.  
 
All C18 acyl-glycines had reduced apparent affinities on F428A. A comparison between acyl-
glycines with double bonds in the ω8, 9 and 10 positions showed a striking relationship 
demonstrating that acyl-glycine with a double bond in ω8 position was markedly affected whilst 
the acyl-glycine with a double bond in the ω10 position was only mildly affected by the mutation 
(Figure 5.15B) For C16 acyl-glycines, the activity was also altered by the position of the double 
bond; the ω11 compound had activity on F428A comparable to WT GlyT2, but shifting the 
double bond to the ω7 position considerably reduced the IC50 (5.8 µM) and max. inhibition 
(56.5%). Sensitivity of F428A to the only C14 acyl glycine was also reduced (IC50 >30 µM). 
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Figure 5.16. Acyl amino acids inhibit glycine transport currents of F428A mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of lipids. A. Concentration–inhibition curves for positively charged 
compounds OLCarn and 47. B. Concentration–inhibition curves for C18 acyl-glycine 
compounds 2, 7, and 8. C. Concentration–inhibition curves for C16 acyl-glycine compounds 
16 and 18. D. Concentration–inhibition curves for acyl-glycine compounds 1 and 20. The 
responses are normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis. 
WT GlyT2 data has been shown in the previous chapters but is included for comparison (black 
curves). F428A is shown in orange.
 
 
The compounds that had reduced activity at F428A transporters all possessed a double bond 
the approximate same distance from the head group (Figure 5.17). F428 may therefore 
comprise part of the lipid binding site where the double bond interacts, or where the kink in 
the acyl tail ideally fits into a cavity. The distance from the side chains of W563 in TM8 and 
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F428 in TM5 is approximately 10 Å (in our GlyT2 model), which is similar to the chain length 
of 9 carbons between the head group and double bond (assuming a C-C bond length of 1.5 Å 
and an angle of ~110º). This supports the head specific (W563L) and tail specific (F428A) 
mutant data, and suggests the binding site may lie within this region.  
 
Figure 5.17. Structures of select acyl-glycine analogues: where acyl chains of different 
lengths possess double bonds the same distance from the head group  
 
5.2.8 Docking of oleoyl D-Lys suggests a lipid binding cavity comprised of 
residues from EL4, TM5, and TM8 
In order to better understand the proposed binding site, dynamic docking of our GlyT2 model 
with C18 ω9 D-Lys was performed by Mitchell Blyth and Dr Megan O’Mara at the Australian 
National University. Residues identified by mutagenesis were defined as potential sites of 
interaction and allowed to move during the simulation. Top scoring binding locations and 
orientations were then docked into the protein structure. Two binding sites were observed 
(Figure 5.18). One of the sites consists of a cavity comprised of EL4, TM5, and TM8, with the 
D-Lys headgroup sandwiched between EL4 and the top of TM8, and the acyl tail buried among 
conserved aliphatic residues behind TM5 and TM8 (“site A”; purple spheres; Figure 5.18C).  
C18 ω9 
C16 ω7 
C14 ω5 
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Figure 5.18. GlyT2 model with oleoyl D-Lys docked in site A (purple spheres) and site B 
(yellow spheres). A. Reverse face in plane of the membrane B. Top down. C. Close up of 
“site A”: EL4, TM7, and TM8 with mutated residues and D. Top down view. EL4 is shown in 
orange, mutants are shown in cyan sticks, and I545 is shown in green sticks. A Monte Carlo 
search algorithm was employed to determine potential binding locations and ligand 
orientations of oleoyl D-Lys on the GlyT2 model. VinaDock was then used to assemble the 
final docked structure. Docking performed by Mitchell Blyth (ANU). 
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Aromatic residues, Y550 and W563, appear to directly interact with the head group (Figure 
5.18D), which may account for the high potency of acyl inhibitors with a positively charged or 
aromatic head groups with the potential for form cation-π and π-π interactions respectively. 
While the hydrophobic tail makes contacts with TM5 and TM8, it did not appear to directly 
interact with the side chains of L569 or F428. These residues may therefore be indirectly 
involved, forming the shape of the binding site. The unsaturated acyl tail would have a 
substantial kink and may only be accommodated by a certain shaped binding cavity; mutations 
that may alter the shape of the cavity could therefore only affect inhibitors with certain tails 
which could explain the tail selectivity of these mutants. Alternatively, the docking may be 
unreliable if the binding site is on the outside of the transporter, partially comprised of 
membrane phospholipids. A high resolution structure of GlyT2 with a lipid inhibitor bound 
would provide further insight into inhibitor-transporter interaction. 
5.2.9 Comparison with lipid binding membrane proteins 
The “site A” cavity is not aqueously accessible, and poses the question of how lipid inhibitors 
are able to access this site. This is reminiscent of the G-protein coupled receptor family, where 
ligands have been crystallised in pockets occluded from the aqueous surroundings (Chrencik 
et al., 2015; Hanson et al., 2012; Hua et al., 2016; Taniguchi et al., 2017). For example, the 
sphingosine-1-phosphate receptor has a large N-terminal helix which sits above the 7 
transmembrane helices and the antagonist ML056 has been resolved in a cavity below this N-
terminal cap (Figure 5.19; Hanson et al., 2012). There is an opening between TM1 and TM7 
which would provide an opening for ligands to access the final binding site by first inserting 
into the bilayer and squeezing between membrane exposed helices. It is possible that lipid 
inhibitors of GlyT2 access the aqueously inaccessible “site A” via a similar mechanism. 
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Figure 5.19. Sphingosine-1-phosphate receptor bound to antagonist ML056 (green 
spheres). A. In plane of the membrane, B. Top down. N-terminal helix shown in purple, TM1 
in red, and TM7 in blue (Hanson et al., 2012) (adapted from PDB: 3V2Y). 
 
Similarly, the recent crystal structure of the lysophosphatidic acid receptor 6 (LPA6) possesses 
a large vertical gap in TM4 and TM5 that spans the length of the extracellular membrane leaflet 
(Tanigushi et al., 2017). This gap appears to be occupied by a monoolein molecule which may 
overlap with the LPA acyl chain binding site. Subsequent docking of this site with 2-LPA (2-
linoleoyl (18:2)-LPA) proposes 3 potential binding models (Figure 5.20) with the acyl tail in the 
TM4-TM5 cleft surrounded by aliphatic residues, and the head group in either the central cavity 
(Figure 5.20 a, b), or on the outer surface of the receptor (Figure 5.20c). Mutation of potential 
head group residues suggests the head group lies in the central cavity (a or b), and acyl chain 
stretched into the membrane cleft. It is suggested that selectivity for LPA acyl chains is due to 
structural features (shape/size) of this cleft. 
- 112 - 
 
 
Figure 5.20. Potential LPA binding (3 models a-c) obtained from docking simulations 
from top down (left) and in plane of the membrane (right). 2-LPA is in spheres with carbons 
(grey), phosphates (yellow). Potential head group residues are shown in blue sticks. Tail 
binding residues are shown in blue sticks and semi-transparent spheres. (Taniguchi et al., 
2017). 
 
Head group and tail group selective GlyT2 mutants suggest that acyl amino acids bind with 
their head group towards the central cavity (between EL4 and TM8), and their tail groups 
adjacent to membrane bound helices (TM5 and TM8). As it does not line “site A”, it is predicted 
that the F428A mutant GlyT2 is selecting for certain tails through changes in the shape of the 
acyl binding pocket. An additional lipid site was also observed in the oleoyl D-Lys docked 
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GlyT2 model where the head group is buried between helices TM5, TM7, and TM8 with the 
acyl tail extending out into the membrane (“site B”; yellow spheres; Figure 5.18). While mutant 
data suggests “site A” is more likely, one of the residues identified in the initial mutant screen, 
F515, appears to stick out into the membrane (Figure 5.21) adjacent to oleoyl D-Lys in “site 
B”. Converse to other mutant GlyT2 transporters, F515W appeared to have increased 
inhibition by 1 µM OLCarn (Figure 5.5). 
5.2.10 F515W in TM7 increases efficacy and the reversibility of OLCarn 
On WT GlyT2, NAGly, NOGly, and OLCarn are partial inhibitors (Wiles et al., 2006; Carland 
et al., 2013) (Figure 5.22A). On The F515W mutant however, these compounds are able to 
act as full inhibitors at high concentrations (Figure 5.22B). F515W increases the % max. level 
of inhibition, but not the apparent affinities (Table 5.2), which suggests this residue may not 
be important for binding, but is important in the mechanism of inhibition. 
 
Figure 5.21. Location of F515 on GlyT2 in plane of the membrane. EL4 is shown in orange, 
TM7 shown in purple, and TM8 shown in teal. F515 is shown in cyan spheres. I545 is shown 
in green spheres. 
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Figure 5.22. Acyl amino acids inhibit glycine transport currents of F515W mutant GlyT2 
transporters expressed in Xenopus laevis oocytes. Glycine transport currents were 
measured in the presence of NAGly (1), NOGly (2), and OLCarn. A. Concentration–inhibition 
curves for GlyT2 B. Concentration–inhibition curves for F515W. The responses are 
normalized mean values ± SEM (n ≥ 3 cells) fit using least-squares analysis. WT GlyT2 data 
is included for comparison (black curves). F515W is shown in green.
 
Acyl-glycine inhibitors, including NAGly and NOGly, are fully reversible 5 minutes post 
inhibition, as indicated by a restoration of glycine transport currents. OLCarn however, is very 
slowly reversible, and currents do not return to pre-exposure levels in the timeframe of the 
assay (Figure 5.23A). At time 0, F515W had a higher level of inhibition compared to WT GlyT2, 
and therefore begins the washout time course with a lower I/Imax. Despite this, transport 
recovery is much faster for F515W (Figure 5.23B); this mutation not only converts OLCarn into 
a full inhibitor but also increases reversibility. 
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Figure 5.23. Washout of 1 µM OLCarn on WT GlyT2 and TM7 F515W mutant GlyT2 
transporters. Glycine (open bar) is applied to generate an inward current which is inhibited 
by 1 µM OLCarn (grey bar) for 4 minutes. 30 µM glycine was applied at 5 minute intervals 
throughout a 25 minute wash with ND96 buffer. Maximal transport current and subsequent 
level of inhibition are marked with grey dashed lines. 
 
I propose that the increase in efficacy and rate of washout is related to the mechanism of 
access for lipid inhibitors to their site. In the inward-open LeuT structure, TM7 partially forms 
a 310 helix where F515 (I in LeuT) is located (Krishnamurthy & Gouaux, 2012). These atypical 
310 helices are longer, thinner, and more likely to unravel. TM5 has similarly been shown to 
partially unwind in the multi-hydrophobic amino acid transporter (MhsT) from Bacillus 
halodurans, where unwinding is triggered by a GlyX9Pro motif that opens an intracellular 
pathway (Malinauskaite et al., 2014). GlyT2 shares this TM5 GlyX9Pro motif and unwinding in 
both TM5 and TM7 may fascitate insertion of acyl inhibitors. 
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It has also been shown by Dr Megan O’Mara (ANU, unpublished data) that in molecular 
dynamics similations of acyl amino acids in a typical POPC membrane, compounds insert into 
the membrane and distribute themselves on both the extracellular and intracellular leaflets 
(Figure 5.24). Compounds were then observed to dip below the phospholipid head groups. 
F515 lies approximately adjacent to the phospholipid head group:acyl chain interface of the 
surrounding membrane, and is suitably located to be the first point of contact for burrowing 
lipids. It is proposed that acyl amino acids must first traverse the cell membrane where they 
interact with F515 and insert between helices in “site B, compounds are then able to access 
their final binding site “site A” to cause inhibition. The F515W mutation may accelerate this 
insertion by favouring amphipathic interactions. Tryptophan residues are also known to 
facilitate movements of proteins within the membrane (Kachel et al., 1995), and therefore may 
favour certain conformations where lipid inhibitors bind. 
Figure 5.24. Molecular dynamics simulation of acyl inhibitors in a POPC/cholesterol 
membrane. POPC membranes with 20% cholesterol and 5% acyl inhibitor were run in 
atomistic simulations for 100 ns. A. NAGly. B. OLCarn. MD simulations were performed by 
Michael Thomas (ANU). 
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Table 5.2. IC50 values and % max. inhibition for mutant GlyT2 transporters 
Mutation Compound IC50 (nM) % Max. inhibition 
GlyT2 
I545L oleoyl L-Val >10 µMa 22.5 ± 8.0b**** 
 oleoyl L-Asp >10 µMa 4.9 ± 6.4**** 
 oleoyl L-Trp >10 µMa 20.2 ± 1.7**** 
 oleoyl L-Lys 443 (270 – 804) 80.7 ± 4.8 
Y550L NOGly 829 (65.0 – 4170) 34.8 ± 9.1** 
 OLCarn >3 µMa 17.3 ± 1.4**** 
 oleoyl L-Val 2930 (1680 – 5130) 57.0 ± 5.1** 
 oleoyl L-Leu 437 (214 – 8920) 41.1 ± 6.2* 
 oleoyl L-Ser >3 µMa 11.2 ± 1.6**** 
 oleoyl L-Asp >3 µMa 7.0 ± 0.8b**** 
 oleoyl L-Trp >3 µMa 16.5 ± 1.7**** 
 oleoyl L-Arg >3 µMa 9.3 ± 1.4**** 
 oleoyl L-Lys 210 (78.6 – 559) 48.2 ± 4.1**** 
 oleoyl D-Lys >3 µMa 38.4 ± 10.0*** 
 C16 ω3 L-Lys 1040 (420 – 2560) 63.1 ± 9.9* 
P561S NOGly 564 (245 – 1300) 62.1 ± 4.8 
 OLCarn >3 µMa 31.6 ± 5.2**** 
 oleoyl L-Val 753 (455 – 1250) 94.5 ± 4.7 
 oleoyl L-Ser 580 (276 – 1220) 80.3 ± 7.3 
 oleoyl L-Asp 2540 (1490 – 4350) 58.2 ± 4.7 
 oleoyl L-Trp 318 (153 – 663) 61.4 ± 4.2*** 
 oleoyl L-Lys 69.2 (31.8 – 151) 71.5 ± 4.8 
 oleoyl D-Lys 558 (247 – 1260) 76.7 ± 8.1 
W563L NOGly 755 (317 – 1800) 46.6 ± 4.0 
 OLCarn >3 µMa 34.7 ± 3.2*** 
 oleoyl L-Val 7510 (1090 – 52000) 56.3 ± 9.1
b 
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 oleoyl L-Ser 661 (221 – 1980) 62.3 ± 5.3 
 oleoyl L-Asp 1160 (477 – 2800) 74.9 ± 7.5 
 oleoyl L-Trp >3 µMa 42.9 ± 2.6**** 
 oleoyl L-Lys 175 (110 – 277) 73.5 ± 3.3 
 oleoyl D-Lys >3 µMa 42.1 ± 7.7** 
L569F NAGly 3590 (430 – 30200) 63.7 ± 19.0 
 NOGly >10 µMa 32.5 ± 3.6*** 
 OLCarn 1200 (267 – 5360) 45.5 ± 7.0
b** 
 oleoyl L-Lys 301 (157 – 577) 76.8 ± 5.8 
F428A NAGly 14400 (3540 – 58600) 64.7 ± 6.6
b 
 NOGly >10 µMa 25.4 ± 4.9**** 
 OLCarn >3 µMa 22.7 ± 3.0b**** 
 oleoyl L-Lys >3 µMa 39.2 ± 2.3b**** 
 C18 ω8 Gly >10 µMa* 13.2 ± 2.7**** 
 C18 ω10 Gly 776 (83.8 – 7180) 25.3 ± 5.3** 
 C16 ω7 Gly 5760 (2220 – 1490) 56.5 ± 7.8** 
 C16 ω11 Gly 4810 (2620 – 8830) 103 ± 7.7 
 C14 ω5 Gly >30 µMa 33.4 ± 3.0b*** 
F515W NAGly 4240 (2000 – 8980) 94.4 ± 5.6
b 
 NOGly 612 (391 – 957) 89.6 ± 4.9* 
 OLCarn 239 (125 – 456) 105 ± 6.0*** 
GlyT1 
L425I NAGly >10 µMa 31.6 ± 6.9 
 NOGly >10 µMa 28.5 ± 5.3b 
 OLCarn 195 (92.4 – 411) 74.6 ± 5.3*** 
Compounds were tested for inhibition of glycine transport on Xenopus laevis oocytes expressing mutant 
GlyT1 and GlyT2 transporters. n ≥ 3 with measurements taken from at least 2 batches of oocytes. Data 
presented are mean and 95% confidence intervals or mean ± SEM.   
aWhere significant inhibition was not reached, IC50 are presented as greater than the maximum 
concentration of each compound applied. 
bWhere inhibition was insignificant and could not be accurately calculated by curve fitting values given 
are the % inhibition at the highest concentration of inhibitor used. 
p values are represented from one way ANOVAs or two-tailed t-tests as described in Methods. 
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5.3 Conclusions 
In this chapter I identified a number of residues important for acyl amino acid binding and their 
mechanism of inhibition. Docking of oleoyl D-Lys revealed 2 potential binding sites: site A is a 
buried cavity comprised of residues in EL4, TM5, and TM8; and site B is partially membrane 
exposed, where the head group embeds between TM5 and TM7 and the acyl tail extends into 
the lipid bilayer. I propose that both sites are functionally relevant to the mechanism of 
inhibition. Firstly, the acyl inhibitors insert into the membrane (Figure 5.25; 1) and snorkel 
below the phospholipid head groups (2) . Compounds can then enter GlyT2 via site B (3), to 
access the buried site A cavity (4). Once in the final binding site, transport is arrested (5). 
Figure 5.25. Proposed mechanism of inhibition by acyl inhibitors of GlyT2. Lipids insert 
into the bilayer (1), migrate within the membrane and dip below phospholipid head groups (2), 
interact with F515 and enter site B (3), wiggle between helices to site A (4), bind between TM8 
and EL4 to prevent transport (5). 
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Mutations to residues at the top of TM8 and in EL4 possess differential selectivity for head 
groups and may form part of the head group binding site. Aromatic residues in this area may 
sandwich head groups, and explain the high potency for acyl amino acids with positively 
charged and aromatic head groups. Similarly, mutations to the medial regions of TM5 and 
TM8 cause acyl tail group selective disruption of inhibition, and may form a hydrophobic pocket 
that is restricted by size and/or shape and only allows certain tail configurations to fit. As GlyT2 
transitions to the inward facing conformation, EL4 shifts closer towards TM8. Lipid binding 
between EL4 and TM8 may “glue” these two regions together, creating a transporter that is 
stable in a transport-unfavourable conformation. In a similar manner to how cholesterol 
stabilises an outward facing conformation of dDAT by preventing the movement of TM1a 
(Hong & Amara, 2010; Penmatsa et al., 2013; Zeppelin et al., 2018), I hypothesize that acyl 
inhibitors stabilise GlyT2 by preventing further movement of EL4. Many acyl amino acids are 
only partial inhibitors, which suggests there is flexibility in the lipid bound conformation to allow 
for some glycine transport. While the mutagenesis data presented in this thesis is highly 
suggestive, combining this data with visualisation of acyl inhibitor bound GlyT2 would 
unambiguously discern the inhibitor binding site. 
  
- 121 - 
 
Chapter 6: Final discussion and future directions 
6.1 Summary of key findings 
In this thesis, I have designed two series of lipid compounds and determined their structure 
activity relationship for a number of inhibitory characteristics that are important in determining 
optimal inhibition of GlyT2. A number of relatively high potency inhibitors were identified, one 
of which has since been tested in preliminary studies of an animal model of neuropathic pain. 
I have also explored the molecular determinants of GlyT2 lipid inhibition to tease out the 
binding site and potential mechanism of action. 
The first study outlined in chapter 3, described a series of compounds where the glycine head 
group was conjugated to acyl tails of varying length (C14-C18) and saturation. I found that 
reduction in tail length resulted in a loss of apparent affinity, with the most potent compound 
possessing a C18 tail with a medial double bond. It was also shown that shifting the double 
bond to the lateral ends of the C18 carbon chain produced compounds that were inactive. 
Inactivity was also conferred for compounds with a double bond in the trans configuration 
which suggests that cis tails provide a kink that fits ideally within a defined acyl binding site. 
For C16 compounds, the position of the double bond governed whether inhibition was full or 
partial, an important consideration when designing therapeutics that target GlyT2. 
In chapter 4, a potent C18 tail with a medial double bond (oleoyl) was attached to amino acid 
head groups that were aliphatic, negatively charged, polar, aromatic, or positively charged. It 
was shown that compounds with positively charged or aromatic head groups conferred the 
highest apparent affinity, while those with an aliphatic or negatively charged head group 
possessed no improved affinity compared to the simplest amino acid, glycine. It was also 
observed that L- are more active than D- enantiomers with activity decreasing as side chains 
became larger, particularly for D- aromatic compounds which did not significantly inhibit GlyT2. 
In addition to the amino acid sidechain being a significant binding moiety, the backbone 
carboxylic acid was also determined to provide important binding interactions. 
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A number of lysine-like compounds were designed which displayed a reduction in apparent 
affinity as the carbon linking the NH3+ group became shorter. Conjugation of the L-Lys head 
to tails of varying length and saturation still produced potent GlyT2 inhibitors, even in the case 
of C18 ω5, which was shown to produce an inactive compound in chapter 3 when conjugated 
to a glycine. Designing lipid inhibitors is not as straightforward as pick-and-mix; where a tail 
with a certain desired characteristic (full or partial) can be attached to a head group of high 
potency in order to produce an ideal inhibitor. Any next generation of lipid compounds will 
therefore need to be tested in a similar assay to determine their activity. It would be of worth 
however, to produce a new series where the L-Lys (or D-Lys) head is conjugated to varying 
acyl tails, as it has been shown that C16 ω3 L-Lys confers a higher potency (10.5 nM). In the 
low nanomolar range even small shifts can push the boundaries to make a compound more 
efficacious. In this study oleoyl  D-Lys was further examined and shown to be stable in plasma 
and microsomes; able to cross the BBB; and produce analgesia in a preliminary rat model of 
neuropathic pain. 
Lastly, in chapter 5, I investigated residues that were either in close proximity to EL4, or were 
in a position to alter conformational dynamics of EL4, to determine their role in inhibition by 
lipid inhibitors. Using site-directed mutagenesis, and subsequent dynamic docking, it was 
determined that residues in EL4, TM5, and TM8 comprise the putative lipid inhibitor binding 
site (site A); where the head group is coordinated by Y550 and W563, and the acyl tail lines 
an hydrophobic cavity that is shaped by F428 and L569. Using dynamic docking, a second 
lipid binding site (site B) was observed in a membrane exposed cavity that overlaps with site 
A (Figure 6.1), where a membrane facing residue F515, when mutated, can alter the maximal 
level of inhibition and reversibility of compounds.  
I propose that site A is the high affinity inhibitor binding site, as alteration of single residues 
within this site abolish or drastically alter inhibitor activity. The majority of residues lining site 
A are branched chain aliphatic residues (Figure 6.1B) which would define the shape of the 
binding cavity and provide hydrophobic interactions for the acyl tail. In addition to Y550 and 
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W563, a third aromatic residue (F567) points in towards the head group and may influence 
binding of lipid inhibitors, which could be further explored using mutagenesis. The effect of 
altering aliphatic residues in the hydrophobic cavity may be difficult to discern, as the tail 
groups of these compounds are flexible and may be able to adopt subtly different binding 
conformations. Lipid tails would also provide many points of contact for a large number of 
hydrophobic interactions, and altering one point of interaction may be insufficient to observe 
changes in activity. Perhaps an approach to increase the bulk of side chains to plug this cavity 
will adequately obstruct lipid binding. 
 
Figure 6.1. Residues lining (within 3 Å) the oleoyl D-Lys site A and site B. Residues are 
shown in sticks and coloured A. purple (site A), yellow (site B), and green (overlapping site). 
B. aliphatic (orange), aromatic (blue), and negatively charged or polar (pink).  
Aromatic residues are also present at the proposed entrance point where F515 lies. As 
aromatic residues appear to coordinate the head group in site A and confer high affinity 
binding, aromatic residues in site B may attract lipids within the membrane and facilitate their 
insertion in between TM helices. I propose that site B is a transient site of access where lipids 
first diffuse into the bilayer before worming between helices TM5 and TM7, to reach site A. 
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Once bound in site A, lipid inhibitors stick between aromatic residues in both TM8 and EL4 to 
glue these regions together and prevent transport of glycine. 
6.2 Future Directions: Resolving protein-lipid interactions 
The research presented in this thesis has identified a large pool of lipid GlyT2 inhibitors that 
could be developed for the treatment of neuropathic pain. In order to further improve these 
compounds it would be instructive to understand in more detail how allosteric lipids interact 
with GlyT2 to cause inhibition. In the following sections I will discuss different approaches in 
the study of protein-lipid interactions (sections 6.2 and 6.3) and then discuss the ideal 
properties of a GlyT2 inhibitor for optimal use in vivo (section 6.4). 
6.2.1 Measuring lipid binding to membrane proteins 
Using an IC50 value to measure the activity of lipid inhibitors gives information on the 
compounds relative potencies, which allows for comparison within the series and can identify 
any changes in activity on a mutant transporter. Inhibition response curves also inform the 
effectiveness of an inhibitor, and can indicate how transport may be affected in vivo to reduce 
glycine reuptake. This approach does not however directly measure binding, which is required 
to measure interactions between ligand and protein. It is more difficult to measure binding of 
a ligand to a membrane protein in its native environment and requires functional, folded 
protein. 
Isothermal titration calorimetry (ITC) is a technique that can be used to measure 
thermodynamic parameters to describe binding with high sensitivity, and has been applied to 
the study of protein interactions with small ligands and ions, and to larger macromolecules 
including nucleic acids and other proteins (Leavitt & Freire, 2001). ITC does not require 
labelling of the protein or ligand, and a single titration can be used to calculate binding affinity 
and stoichiometry (Rajarathnam & Rosgen, 2014). More recently, ITC has been used 
successfully to monitor ligand binding to membrane proteins, including the human glycine 
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receptor (Wohri et al., 2013) and the E. coli Na+/H+ antiporter NhaA (Maes et al., 2012). ITC 
was also used to locate ion binding sites in NhaA by comparing the thermodynamic signatures 
of WT and mutant antiporters (Maes et al., 2012). 
For membrane proteins, ITC is carried out on detergent solubilised protein, and protein-
detergent interactions can contribute to or mask the signal of binding events (Rajarathnam & 
Rosgen, 2014). This may complicate the measurement of lipid inhibitor binding to GlyT2, as 
specific protein-lipid interactions may be difficult to interpret. Nonetheless, ITC would be an 
interesting approach to study GlyT2 and may provide information on lipid binding, as well as 
indicate the ordering of flexible lipid tails. While mutant data in this thesis suggests that 
inhibition of GlyT2 is via a single high specificity site, it remains that lipids are often found 
bound to multiple sites on a protein. Multiple binding events and their strength of interaction 
could be observed using this technique. 
Another technique to monitor protein-lipid interactions involves using mass spectrometry of 
intact membrane proteins (native-MS), where purified protein is ionised and liberated from 
detergent micelles into the gas phase, where it remains folded and can be resolved on a typical 
mass-charge spectrum (Laganowsky et al., 2013). As the detergent micelle is stripped via 
collisional activation, any lipids that remain are tightly bound and can be observed in the 
spectrum. Since its development, native-MS has been integral in increasing the understanding 
of how lipids influence the structure and function of membrane proteins (Bechara et al., 2015; 
Bechara & Robinson, 2015; Cong et al., 2016; Laganowsky et al., 2014; Laganowsky et al., 
2013; Landreh et al., 2016; Liu et al., 2017; Patrick et al., 2018; Pliotas et al., 2015).  
While folded membrane proteins can exist in the gas phase, unfolding can occur under high 
collisional activation (Laganowsky et al., 2013). A study by Laganowsky et al., (2014) used 
this principle to measure lipid binding through their ability to maintain the stability of folded 
protein. It was found that in all cases different numbers of bound lipids conferred stability and 
that each membrane protein possessed different selectivity. Lipid binding to the 
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mechanosensitive channel was non-selective, whereas stabilisation of the ammonia channel 
(AmtB) was head group selective; with cardiolipin and phosphatidylglycerol providing 
increased stability, while phosphatidic acid and phosphatidylserine did not. Subsequent 
crystallisation of AmtB in the presence of PG, revealed a structure which was similar to the 
previously detergent crystallised AmtB (Khademi et al., 2004), but with a loop region forming 
a specific PG binding site. Asparagine and glutamate residues were observed to cradle the 
head group while a phenylalanine residue interacted with an acyl tail. A tryptophan residue 
was also shifted 4 Å and rotated 160º to a position which would interact with membrane 
phospholipid groups.  
In addition to identifying lipids bound to membrane proteins, their strength of interactions can 
also be quantified using native-MS at a controlled temperature to measure thermodynamic 
parameters to represent binding modes and conformational ordering (Cong et al., 2016).  
Lipids with 1-palmitoyl-2-oleoyl (PO) tails and a range of head groups were applied to AmtB 
which was previously shown to possess lipid head group selectivity. It was observed that there 
was greater enthalpy upon binding of POPG, and a corresponding decrease in entropy which 
is believed to be due to rearrangement of AmtB to form the lipid-bound conformation. Lipids 
with a PG head group attached to 1-, 2- saturated C12-, C14-, or C16- tails were then 
examined for changes in binding; as tails became longer, the entropy became more favourable 
which was accompanied by an enthalpic penalty indicative of more hydrophobic interactions. 
Native-MS of proteins at a set temperature allows for the determination of an equilibrium 
dissociation constant (Kd) of binding. This is a direct measure of affinity, rather than effective 
inhibitory concentrations (IC50). Binding of multiple lipid types and their influence on 
subsequent binding events can also be monitored using this technique (Patrick et al., 2018). 
It was found for AmtB that different lipid pairs produced different allosteric modulation 
(indicated by a “coupling factor”), and that most lipid combinations had a positive coupling 
factor, however some possessed negative coupling factors, which suggests that lipid binding 
can force both favourable and unfavourable conformations for subsequent binding events. 
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Lipid inhibition of GlyT2 is non-competitive and proposed to act via an allosteric site. Native-
MS is a valuable tool to elucidate specific membrane protein-lipid interactions and would be a 
useful approach for studying interactions between lipid inhibitors and GlyT2. Native-MS may 
inform how lipid inhibitors bind, and with what affinity; and could also help in understanding 
their mechanism of action.   
6.2.2 Advances in structural biology to study membrane proteins in a more 
native environment 
Membrane protein structural biology remains a challenging field as a result of the inherent 
instability of these proteins outside their membrane environment. There are a number of 
factors contributing to the instability of membrane proteins; their surfaces are highly 
amphipathic and must be supported by a lipid or detergent scaffold, and they contain highly 
flexible regions which can hinder crystal formation (Carpenter et al., 2008). While X-ray 
crystallography has typically been utilised to visualise membrane proteins, there are a number 
of newer techniques which attempt to circumvent these problems to obtain protein structures. 
Traditional X-ray crystallography often requires the use of thermostable mutants where 
residues are substituted or entire flexible sections removed, as in the case of NSS transporters 
where the first 20 amino acids of the N-terminus and 42 amino acids from EL2 were removed 
to capture the structure of dDAT (Penmatsa et al., 2013). Unlike X-ray crystallography, cryo-
electron microscopy (cryo-EM) can obtain structures from non-crystalline proteins. In cryo-
EM, proteins are rapidly frozen in their flexible, native states and can accommodate flexible 
regions of proteins. High energy electrons are then used to capture 2D images of these flash 
frozen proteins from which 3D structures can be constructed (Spiegel et al., 2015; 
Vinothkumar, 2015). GlyT2 possesses the longest flexible regions of proteins in this family 
(199 and 102 amino acids in N-terminus and EL2 respectively), which have been excluded 
from the homology model used in Chapter 5 of this thesis as they are not present in the 
template dDAT structure (Penmatsa et al., 2013). Visualisation of native GlyT2 by traditional 
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methods is therefore unlikely and perhaps cryo-EM could be useful in observing more of the 
flexible regions of this protein. 
The use of Cryo-EM has been limited by low resolution limits (~3 Å) and size limits (>100 kDa), 
but with the advent of new technologies proteins have recently been visualised at atomic 
resolution (Vinothkumar, 2015).  Cryo-EM has traditionally been used to elucidate structures 
of large protein complexes as errors occur when aligning individual images for smaller 
proteins, which may hinder visualisation of monomeric LeuT (~58 kDa) and GlyT2 (~88 kDa). 
Recently, a cryo-EM structure of haemoglobin (64 kDa, 3.2 Å) has been revealed using a 
phase plate, which improves signal-to-noise and reduces the image contrast problem 
(Khoshouei et al., 2017). With improvements in this technology, visualisation of smaller 
proteins, such as GlyT2, may be possible. 
To prepare membrane proteins for structural analysis they must be purified from the host cell 
membrane. Isolation of membrane proteins typically involves detergent solubilisation to mimic 
lipid bilayers and maintain a protein folded in a functional conformation (Carpenter et al., 
2008). As previously discussed, many membrane proteins specifically bind lipids that are 
essential for their function, therefore solubilising membrane proteins in detergent may remove 
tightly bound lipids and hold a protein in its non-native state. As a result of this purification 
process there are few X-ray structures of membrane proteins resolved with lipids bound. One 
such structure is the trimeric betaine transporter (BetP) which has been solved with 8 POPG 
lipids mimicking the lipid bilayer or bound in areas thought to mediate oligomeric interactions 
and gating (Koshy et al., 2013). Structural evidence from X-ray crystallography can suggest 
roles for lipid interactions which can be strengthened using other techniques. For example, 
Fourier transform infrared (FTIR) spectroscopy of proteins reconstituted into closely packed 
two-dimensional crystals of lipids can be used to monitor the stretching modes of lipid head 
groups and acyl tails for different transport conditions (Lewis & McElhaney, 2013). Using this 
technique to monitor K+ binding to BetP reconstituted in negatively charged lipids shows 
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phospholipid head groups changing their electrostatic and H-bonds in a K+ dependent manner 
which supports the original crystallographic data (Güler et al., 2016). 
Detergents also may not cover all hydrophobic areas of the protein and this can cause 
hydrophobic mismatch, causing proteins to aggregate. It has previously been shown that the 
function of LeuT can be affected by surrounding lipids; the presence of a single membrane 
exposed residue of LeuT causes hydrophobic mismatch in membranes (Mondal et al., 2013); 
and by titrating concentrations of the detergent, n-dodecyl-β-D-maltoside, the stoichiometry of 
transport can be altered (LeVine et al., 2016). Clearly, the membrane environment can alter 
the functional and structural biology of membrane proteins and should be considered in their 
studies. 
Techniques that study membrane proteins in a more membrane-like environment, such as 
lipidic cubic phase (LCP) crystallisation and incorporation into nanodiscs can help to capture 
native states. Following their isolation, membrane proteins can be reconstituted into LCPs, 
which forms a matrix that closely mimics lipid bilayers and supports membrane proteins 
(Landau & Rosenbusch, 1996). LCP crystals form in these bilayers with additional protein-
protein crystal contacts that are stabilised by the presence of lipid (usually monoolein). LCP 
often yields stable protein crystals which can be used to determine X-ray crystal structures 
(Zabara et al., 2017). 
Nanodiscs are high density lipoprotein particles made by solubilising a membrane protein with 
detergent in the presence of phospholipids and an amphipathic membrane scaffold protein 
(MSP). Following detergent removal, nanodiscs self-assemble with the protein embedded 
within phospholipids, held together by the MSP (Civjan et al., 2003). As the lipid composition 
of nanodiscs can be engineered, they are useful tools to study specific lipid-protein interactions 
(Bayburt & Sligar, 2010).  
While LCP and nanodiscs minimise detergent exposure, detergents are still required to initially 
extract proteins from the host cell membrane. A new strategy to form lipoprotein particles, 
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without the use of detergents, employs styrene maleic acid (SMA) copolymers which self-
assemble into nanoparticles (Scheidelaar et al., 2015). SMA copolymers are membrane 
solubilising agents that utilise the hydrophobic effect to wrap around planar bilayer fragments 
to extract and purify membrane proteins with their surrounding lipids to form SMA lipo-particles 
(SMALPS). Using this technique, membrane proteins never leave the lipid bilayer. It has been 
shown the tetrameric K+ channel (KcsA) can be directly reconstituted into planar lipid bilayers 
forming SMALPS, and single channel measurements performed using electrophysiology (Dörr 
et al., 2014). Additionally, crystal structures of bacteriorhodopsin (Broecker et al., 2017) and 
the E. coli multi drug efflux transporter (Parmar et al., 2018) purified by SMA copolymers have 
recently been solved using LCP and cryo-EM. 
Many functional and structural studies require purified protein, a challenge that is yet to be 
overcome for many mammalian membrane proteins, including GlyT2. The use of detergent-
minimising techniques such as LCP, or the incorporation of proteins into lipoparticles formed 
using MSP mediated nanodiscs or SMA copolymers, may be a promising tool to purify GlyT2 
for the study of lipid-protein interactions. 
6.3 Monitoring conformational dynamics of transport and inhibition 
Mutagenesis data and subsequent docking of lipid inhibitors onto the GlyT2 model have 
established that EL4 has an important role in inhibition. Because it is proposed that EL4 
undergoes large movements from the outward-facing to the inward-facing states, a 
mechanism of inhibition was suggested wherein lipid inhibitors stabilise EL4 and prevent 
critical conformational changes. There are a number of crystal structures of LeuT in various 
states of the transport cycle which can help to infer structural changes; however X-ray 
crystallography is insufficient to visualise dynamic conformational changes, and by relying 
solely on these structures data can be over-extrapolated. Comparison of LeuT crystal 
structures show TM1a tilted by ~45º in the inward-open structure relative to the closed state 
(Krishnamurthy & Gouaux, 2012), and authors suggested that this movement is required for 
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substrate release. Recent research using conformational dynamics has observed TM1a 
movement to be much smaller, and also identify the N-terminus as a region important for 
intracellular gating (Kazmier et al., 2014; Terry et al., 2018). Dynamic studies of membrane 
proteins are therefore required to understand more about conformational changes of transport, 
and could help to propose how lipid-mediated GlyT2 inhibition may occur. 
Single molecule [Förster] fluorescence resonance energy transfer (smFRET) and double 
electron-electron resonance (DEER; also called pulsed electron-electron double resonance) 
are biophysical techniques which measure molecular scale distances (1-10 nm) to describe 
conformational dynamics and intramolecular interactions (Jeschke et al., 2002; Juette et al., 
2014; McHaourab et al., 2011; Sasmal et al., 2016). smFRET relies on donor and acceptor 
fluorophores which are linked to certain areas of the protein; where fluorescence of the 
acceptor and quenching of the donor indicates their relative positions (Juette et al., 2014). 
Distance measurements are similarly measured in DEER where spin-labelled residues 
produce electron paramagnetic resonance spectra which reflect their local environment (G. 
Jeschke, 2012).These techniques can help to capture transient conformations; provide 
information on relative populations of each state and the timing of conformational transitions; 
as well as monitor how each state changes upon binding of substrate, ions, and inhibitors. 
Both smFRET and DEER have been used to monitor alternating access by LeuT to identify 
regions important for transport (Kazmier et al., 2014; Terry et al., 2018; Zhao et al., 2010; Zhao 
et al., 2011).  
smFRET on detergent solubilised LeuT revealed a partially inward-facing intermediate 
structure which is associated with Na+ release from the Na2 site (Terry et al., 2018). In 
substrate free conditions, this state was only sampled 13% of the time, which suggests it may 
be a more rare conformation that is difficult to obtain using traditional crystallographic 
techniques. It was also shown that pre-incubation with Na+ causes thinning of the extracellular 
vestibule which hinders the access of leucine, but not alanine, of the primary substrate site. 
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smFRET has enabled the visualisation of how occupation of certain sites (in this case Na+) 
can allosterically alter substrate binding. 
In a study by Kazmier et al., (2014), using DEER, substrate and Na+ concentrations were used 
to drive isomerisation of LeuT from outward-open to inward-open. It was shown that EL4 
shifted between outward-facing and occluded and is an important region to drive transport. By 
using either n-octyl-β- D-glucopyranoside or n-dodecyl-β- D -maltoside the populations of 
states could be shifted, with n-octyl-β- D-glucopyranoside favouring the outward open state.  
Lipid inhibitors of GlyT2 may act by binding allosterically to GlyT2 and changing access or the 
shape of the primary substrate binding site. They may also stabilise the transporter in a certain 
state that is not transport-favourable. By using dynamic techniques that monitor 
conformational transitions, perhaps an inhibited state could be captured and the mechanism 
of inhibition better understood. DEER spin-labelling and smFRET fluorophores generally rely 
on labelling either native or engineered cysteine residues. GlyT2 contains 23 native cysteines 
which would make creation of a functional cysteine-less template very difficult. Alternative 
labelling strategies, for example incorporation of unnatural amino acids, may help in the use 
of these methods. 
Another approach to monitor dynamic movements of proteins is using computational MD 
studies. MD uses classical equations of motion and energy for each particle in the system to 
observe protein changes. For a typical membrane protein in its native environment the system 
is comprised of not only the protein and aqueous compartments, but the lipid bilayer. This 
requires calculations on ~105 atoms for atomic simulations (Dror et al., 2012). Lipid motions 
(lipid diffusion, flip-flopping, bilayer self-assembly) are slow which makes them difficult to 
detect within the time frame of a simulation (Kandt et al., 2007). To capture each of the 
proposed steps in the mechanism of lipid inhibition of GlyT2, longer simulations will need to 
be performed. 
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The more stable a protein is, the longer it can be run in an MD simulation with confidence that 
conformational changes are genuine (Kandt et al., 2007). Homology models are less stable 
than protein data bank (PDB) structures and their quality is entirely dependent on the quality 
of the template structure (Koehler  et al., 2015). For GlyT2, the homology model used in this 
thesis for the docking of oleoyl D-Lys is based on the outward-occluded dDAT structure (PDB: 
4M48) and was developed using a protein fold recognition (or threading) approach 
(Subramanian et al., 2016). GlyT2 shares ~50% sequence identity with dDAT and the dDAT 
structure and GlyT2 homology model overlap with an RMSD of 1.37 Å, which is appropriate 
for accurate MD simulations (Leman et al 2015). In order to run simulations of a homology 
model for suitably long to observe lipid movements, coarse-grain MD can be used, where 
particles are defined as groups of atoms (for example a residue) (Kandt et al., 2007). 
A recent study by Zeppelin et al., (2018), used both atomistic and coarse-grain MD to examine 
the role cholesterol possesses in altering conformational dynamics of dDAT, hDAT, hSERT, 
and the human noradrenalin transporter from either crystal structures or homology models. It 
was observed that in the absence of cholesterol DAT commences the first steps of transport, 
whereas in the presence of cholesterol no conformational changes take place. This suggests 
that cholesterol stabilises the outward-open conformation to prevent transport, which was 
predicted from the first dDAT structure (Penmatsa et al., 2013). It was also found that 
cholesterol-mediated inhibition was conserved at this site in the SERT and noradrenalin 
transporters. A similar approach for GlyT2 lipid inhibitors could be employed, where 
conformational changes of the oleoyl D-Lys docked protein structure could be compared to 
GlyT2 with no lipid present. MD simulations may help to further discern the mechanism of 
inhibition at GlyT2, which is currently only visualised in a static docked model. 
6.4 Functional implications of glycine transport inhibitors 
Nerve injury and alteration in synaptic pathways within the dorsal horn can give rise to 
neuropathic pain, and a loss of inhibitory neurotransmission can cause disinhibition of pain 
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signalling (Latremoliere & Woolf, 2009; Takazawa & MacDermott, 2010). Inhibitory GABAergic 
neurons are distributed throughout the CNS, while glycinergic neurons expressing GlyR and 
GlyT2 are abundant within the spinal cord dorsal horn. Here, glycine acts in a feed-forward 
inhibitory circuit that separates the innocuous and noxious sensory pathways (Lu et al., 2013). 
It has been shown that following peripheral inflammation there is reduced frequency of GlyR-
mediated currents and a reduction in inhibitory control of spinal lamina I neurons, and that this 
loss of control is via a presynaptic mechanism (Müller et al., 2003). More recently, it was 
observed that there is a loss of glycinergic control over excitatory radial neurons in spinal 
lamina II (Imlach et al., 2016).  
Partial, non-competitive inhibition of presynaptic GlyT2 glycine transporters prolongs the time-
course of glycine at inhibitory synapses in the superficial dorsal horn, which then remains to 
activate GlyRs and increase inhibitory tone (Jeong et al., 2010). Full inhibition, however, has 
been shown to alter the ratio of GABA to glycine release (Xu et al., 2005). It is thought that 
complete blockage of GlyT2 results in an imbalance of GABA:glycine loading into vesicles by 
VIAAT, which ultimately reduces glycine release and inhibitory glycinergic signalling in the 
spinal cord dorsal horn. For therapeutics targeting GlyT2 to be successful, full vs. partial 
inhibition must be addressed; but the question remains – how partial is partial? That is, what 
is the ideal level of inhibition that will provide a balance between slowing reuptake, and still 
allow appropriate glycine recycling? A partial, non-competitive inhibitor should in theory not 
change the equilibrium intracellular glycine concentration, but rather alter the time taken to 
reach equilibrium. In this thesis I identified a large range of allosteric lipid inhibitors with 
differences in maximal level of inhibition and reversibility characteristics. It would be valuable 
to study a few key compounds in brain slices containing inhibitory glycinergic synapses, where 
inhibition of GlyT2 would either increase or decrease glycine in the synapse following 
prolonged exposure. This would help to identify efficacious compounds with ideal 
characteristics that may reduce any adverse side effects when introduced into animal models 
of neuropathic pain. 
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The failure of potential therapeutics can also be due to ineffectiveness as well as an adverse 
side effect profile. Lipid analgesics could be tested in a number of models of chronic pain, for 
example, inflammatory pain induced using a subcutaneous injection of Freund’s Complete 
Adjuvant into the plantar surface of the paw, as in previous studies of NAGly (Succar et al., 
2007). Validating the use of N-acyl amino acids as analgesics in multiple animal models may 
increase the likelihood of their activity as analgesics in humans. While oleoyl D-Lys has been 
shown to cross the BBB via IP injection, the oral bioavailability should be examined, which 
may direct further chemistry to improve the permeability and solubility of lipid inhibitors while 
retaining efficacy, and will become an important consideration in the development of the next 
generation of GlyT2 inhibitors. 
6.5 Conclusion 
The objective of this thesis was to contribute to the understanding of how lipid compounds can 
inhibit the membrane bound transporter, GlyT2. I have greatly expanded the known pool of 
lipid GlyT2 inhibitors, and identified compounds with a broad range of inhibitory properties, 
which can be used as tools to determine ideal in vivo activity. I have also used site-directed 
mutagenesis to begin to unravel the molecular mechanism of inhibition. Further understanding 
of the mechanism of inhibition and design of more effective inhibitors will require the use of 
recent advances in functional and structural biochemical techniques to visualise lipid inhibitors 
bound to GlyT2, and to appreciate the conformational dynamics underlying transport. These 
approaches will greatly contribute to the study of lipid-membrane protein interactions. It is 
hoped that further development of the compounds characterised in this thesis will produce 
clinically relevant therapeutics for the treatment of chronic neuropathic pain. 
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